<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
	<head>
		<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
		<meta http-equiv="Content-Style-Type" content="text/css" />
		<meta name="generator" content="MediaWiki 1.15alpha" />
		<meta name="keywords" content="Venlafaxine,Articles with unsourced statements since March 2009,Antidepressants,Phenethylamines,2,5-dimethoxy-4-bromoamphetamine,2,5-dimethoxy-4-iodoamphetamine,2,5-dimethoxy-4-methylamphetamine,2C-B,2C-C,2C-D,2C-E" />
		<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Venlafaxine&amp;action=edit" />
		<link rel="edit" title="Edit this page" href="/w/index.php?title=Venlafaxine&amp;action=edit" />
		<link rel="apple-touch-icon" href="http://en.wikipedia.org/apple-touch-icon.png" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)" />
		<link rel="copyright" href="http://www.gnu.org/copyleft/fdl.html" />
		<link rel="alternate" type="application/rss+xml" title="Wikipedia RSS Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=rss" />
		<link rel="alternate" type="application/atom+xml" title="Wikipedia Atom Feed" href="/w/index.php?title=Special:RecentChanges&amp;feed=atom" />
		<title>Venlafaxine - Wikipedia, the free encyclopedia</title>
		<link rel="stylesheet" href="/skins-1.5/common/shared.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/common/commonPrint.css?207xx" type="text/css" media="print" />
		<link rel="stylesheet" href="/skins-1.5/monobook/main.css?207xx" type="text/css" media="screen" />
		<link rel="stylesheet" href="/skins-1.5/chick/main.css?207xx" type="text/css" media="handheld" />
		<!--[if lt IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE50Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 5.5000]><link rel="stylesheet" href="/skins-1.5/monobook/IE55Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 6]><link rel="stylesheet" href="/skins-1.5/monobook/IE60Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<!--[if IE 7]><link rel="stylesheet" href="/skins-1.5/monobook/IE70Fixes.css?207xx" type="text/css" media="screen" /><![endif]-->
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Common.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Print.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="print" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Handheld.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" media="handheld" />
		<link rel="stylesheet" href="/w/index.php?title=MediaWiki:Monobook.css&amp;usemsgcache=yes&amp;ctype=text%2Fcss&amp;smaxage=2678400&amp;action=raw&amp;maxage=2678400" type="text/css" />
		<link rel="stylesheet" href="/w/index.php?title=-&amp;action=raw&amp;maxage=2678400&amp;gen=css" type="text/css" />
		<!--[if lt IE 7]><script type="text/javascript" src="/skins-1.5/common/IEFixes.js?207xx"></script>
		<meta http-equiv="imagetoolbar" content="no" /><![endif]-->

		<script type= "text/javascript">/*<![CDATA[*/
		var skin = "monobook";
		var stylepath = "/skins-1.5";
		var wgArticlePath = "/wiki/$1";
		var wgScriptPath = "/w";
		var wgScript = "/w/index.php";
		var wgVariantArticlePath = false;
		var wgActionPaths = {};
		var wgServer = "http://en.wikipedia.org";
		var wgCanonicalNamespace = "";
		var wgCanonicalSpecialPageName = false;
		var wgNamespaceNumber = 0;
		var wgPageName = "Venlafaxine";
		var wgTitle = "Venlafaxine";
		var wgAction = "view";
		var wgArticleId = "520574";
		var wgIsArticle = true;
		var wgUserName = null;
		var wgUserGroups = null;
		var wgUserLanguage = "en";
		var wgContentLanguage = "en";
		var wgBreakFrames = false;
		var wgCurRevisionId = 282506397;
		var wgVersion = "1.15alpha";
		var wgEnableAPI = true;
		var wgEnableWriteAPI = true;
		var wgSeparatorTransformTable = ["", ""];
		var wgDigitTransformTable = ["", ""];
		var wgMWSuggestTemplate = "http://en.wikipedia.org/w/api.php?action=opensearch\x26search={searchTerms}\x26namespace={namespaces}\x26suggest";
		var wgDBname = "enwiki";
		var wgSearchNamespaces = [0];
		var wgMWSuggestMessages = ["with suggestions", "no suggestions"];
		var wgRestrictionEdit = [];
		var wgRestrictionMove = [];
		/*]]>*/</script>

		<script type="text/javascript" src="/skins-1.5/common/wikibits.js?207xx"><!-- wikibits js --></script>
		<!-- Head Scripts -->
		<script type="text/javascript" src="/skins-1.5/common/ajax.js?207xx"></script>
		<script type="text/javascript" src="/skins-1.5/common/mwsuggest.js?207xx"></script>
<script type="text/javascript">/*<![CDATA[*/
var wgNotice='';var wgNoticeLocal='';
/*]]>*/</script>		<script type="text/javascript" src="http://upload.wikimedia.org/centralnotice/wikipedia/en/centralnotice.js?207xx"></script>
		<script type="text/javascript" src="/w/index.php?title=-&amp;action=raw&amp;gen=js&amp;useskin=monobook"><!-- site js --></script>
	</head>
<body class="mediawiki ltr ns-0 ns-subject page-Venlafaxine skin-monobook">
	<div id="globalWrapper">
		<div id="column-content">
	<div id="content">
		<a name="top" id="top"></a>
		<div id="siteNotice"><script type='text/javascript'>if (wgNotice != '') document.writeln(wgNotice);</script></div>		<h1 id="firstHeading" class="firstHeading">Venlafaxine</h1>
		<div id="bodyContent">
			<h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
			<div id="contentSub"></div>
									<div id="jump-to-nav">Jump to: <a href="#column-one">navigation</a>, <a href="#searchInput">search</a></div>			<!-- start content -->
			<table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Venlafaxine.svg" class="image" title="Venlafaxine.svg"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/6/67/Venlafaxine.svg/220px-Venlafaxine.svg.png" width="220" height="228" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2"><a href="/wiki/File:Venlafaxine-3D-balls.png" class="image" title="Venlafaxine-3D-balls.png"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/2/28/Venlafaxine-3D-balls.png/220px-Venlafaxine-3D-balls.png" width="220" height="208" border="0" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Venlafaxine</div>
</td>
</tr>
<tr>
<td align="center" colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="/wiki/International_Union_of_Pure_and_Applied_Chemistry_nomenclature" title="International Union of Pure and Applied Chemistry nomenclature" class="mw-redirect">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="/wiki/CAS_registry_number" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=93413-69-5&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2009/MB_cgi?term=93413-69-5&amp;rn=1" rel="nofollow">93413-69-5</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Anatomical_Therapeutic_Chemical_Classification_System" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/ATC_code_N06" title="ATC code N06">N06</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=N06AX16" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=N06AX16" rel="nofollow">AX16</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/PubChem" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5656" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5656" rel="nofollow">5656</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/DrugBank" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00125" class="external text" title="http://www.drugbank.ca/cgi-bin/show_drug.cgi?CARD=APRD00125" rel="nofollow">APRD00125</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/ChemSpider" title="ChemSpider">ChemSpider</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.chemspider.com/Chemical-Structure.56641" class="external text" title="http://www.chemspider.com/Chemical-Structure.56641" rel="nofollow">56641</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Chemical_formula" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/Carbon" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>17</sub><a href="/wiki/Hydrogen" title="Hydrogen"><span style="color: rgb(77,77,77); font-weight: bold;">H</span></a><sub>27</sub><a href="/wiki/Nitrogen" title="Nitrogen"><span style="color: rgb(0,0,128); font-weight: bold;">N</span></a><a href="/wiki/Oxygen" title="Oxygen"><span style="color: rgb(116,35,35); font-weight: bold;">O</span></a><sub>2</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Molecular_mass" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">277.402 g/mol</td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="/wiki/Simplified_molecular_input_line_entry_specification" title="Simplified molecular input line entry specification">SMILES</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=O%5BC%40%40%5D1%28CCCCC1%29C%28CN%28C%29C%29c2ccc%28OC%29cc2" class="external text" title="http://www.emolecules.com/cgi-bin/search?t=ex&amp;q=O%5BC%40%40%5D1%28CCCCC1%29C%28CN%28C%29C%29c2ccc%28OC%29cc2" rel="nofollow">eMolecules</a></span> &amp; <span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=O%5BC%40%40%5D1%28CCCCC1%29C%28CN%28C%29C%29c2ccc%28OC%29cc2" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/search/?smarts=O%5BC%40%40%5D1%28CCCCC1%29C%28CN%28C%29C%29c2ccc%28OC%29cc2" rel="nofollow">PubChem</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Bioavailability" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">45%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Plasma_protein_binding" title="Plasma protein binding">Protein binding</a></td>
<td bgcolor="#EEEEEE">27%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Drug_metabolism" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE"><a href="/wiki/Hepatic" title="Hepatic" class="mw-redirect">Hepatic</a></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Biological_half-life" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">5 ± 2 hours (parent compound); 11 ± 2 hours (active metabolite)</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Excretion" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE">Renal</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Pregnancy_category" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>C</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Regulation_of_therapeutic_goods" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p>Rx-only, not a controlled drug</p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="/wiki/Route_of_administration" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE">Oral</td>
</tr>
</table>
<p><b>Venlafaxine</b> (brand name <b>Effexor</b>, <b>Efexor</b>) is an <a href="/wiki/Antidepressant" title="Antidepressant">antidepressant</a> of the <a href="/wiki/Serotonin-norepinephrine_reuptake_inhibitor" title="Serotonin-norepinephrine reuptake inhibitor">serotonin-norepinephrine reuptake inhibitor</a> (SNRI) class first introduced by <a href="/wiki/Wyeth" title="Wyeth">Wyeth</a> in 1993. It is prescribed for the treatment of <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depression</a> and <a href="/wiki/Anxiety_disorders" title="Anxiety disorders" class="mw-redirect">anxiety disorders</a>, among other uses. Venlafaxine was the sixth most widely-used brand-name drug and most widely-used brand-name antidepressant based on the retail sales ($2.25bn) in 2006.<sup id="cite_ref-0" class="reference"><a href="#cite_note-0" title=""><span>[</span>1<span>]</span></a></sup></p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Indications"><span class="tocnumber">1</span> <span class="toctext">Indications</span></a>
<ul>
<li class="toclevel-2"><a href="#Approved"><span class="tocnumber">1.1</span> <span class="toctext">Approved</span></a>
<ul>
<li class="toclevel-3"><a href="#Depression"><span class="tocnumber">1.1.1</span> <span class="toctext">Depression</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Off-label_.2F_investigational_uses"><span class="tocnumber">1.2</span> <span class="toctext">Off-label / investigational uses</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Contraindications"><span class="tocnumber">2</span> <span class="toctext">Contraindications</span></a>
<ul>
<li class="toclevel-2"><a href="#Glaucoma"><span class="tocnumber">2.1</span> <span class="toctext">Glaucoma</span></a></li>
<li class="toclevel-2"><a href="#Pregnancy.2C_labor.2C_and_delivery"><span class="tocnumber">2.2</span> <span class="toctext">Pregnancy, labor, and delivery</span></a></li>
<li class="toclevel-2"><a href="#Heart_disease_and_hypertension"><span class="tocnumber">2.3</span> <span class="toctext">Heart disease and hypertension</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Adverse_effects"><span class="tocnumber">3</span> <span class="toctext">Adverse effects</span></a>
<ul>
<li class="toclevel-2"><a href="#Suicide_ideation.2Frisk"><span class="tocnumber">3.1</span> <span class="toctext">Suicide ideation/risk</span></a></li>
<li class="toclevel-2"><a href="#Common_side_effects"><span class="tocnumber">3.2</span> <span class="toctext">Common side effects</span></a></li>
<li class="toclevel-2"><a href="#Less_common_to_rare_side-effects"><span class="tocnumber">3.3</span> <span class="toctext">Less common to rare side-effects</span></a></li>
<li class="toclevel-2"><a href="#Dose_dependency_of_adverse_events"><span class="tocnumber">3.4</span> <span class="toctext">Dose dependency of adverse events</span></a></li>
<li class="toclevel-2"><a href="#Memory_Loss"><span class="tocnumber">3.5</span> <span class="toctext">Memory Loss</span></a></li>
<li class="toclevel-2"><a href="#Discontinuation_Syndrome"><span class="tocnumber">3.6</span> <span class="toctext">Discontinuation Syndrome</span></a></li>
<li class="toclevel-2"><a href="#Serotonin_syndrome"><span class="tocnumber">3.7</span> <span class="toctext">Serotonin syndrome</span></a></li>
<li class="toclevel-2"><a href="#Combined_Serotonin_Toxicity_and_SSRI_Discontinuation_Syndrome"><span class="tocnumber">3.8</span> <span class="toctext">Combined Serotonin Toxicity and SSRI Discontinuation Syndrome</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Available_forms"><span class="tocnumber">4</span> <span class="toctext">Available forms</span></a>
<ul>
<li class="toclevel-2"><a href="#Venlafaxine_extended_release_.28XR.29"><span class="tocnumber">4.1</span> <span class="toctext">Venlafaxine extended release (XR)</span></a></li>
<li class="toclevel-2"><a href="#Generic"><span class="tocnumber">4.2</span> <span class="toctext">Generic</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Overdose"><span class="tocnumber">5</span> <span class="toctext">Overdose</span></a>
<ul>
<li class="toclevel-2"><a href="#Management_of_overdosage"><span class="tocnumber">5.1</span> <span class="toctext">Management of overdosage</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Mechanism_of_action"><span class="tocnumber">6</span> <span class="toctext">Mechanism of action</span></a>
<ul>
<li class="toclevel-2"><a href="#Pharmacokinetics"><span class="tocnumber">6.1</span> <span class="toctext">Pharmacokinetics</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Drug_interactions"><span class="tocnumber">7</span> <span class="toctext">Drug interactions</span></a></li>
<li class="toclevel-1"><a href="#Physical.2Fchemical_properties"><span class="tocnumber">8</span> <span class="toctext">Physical/chemical properties</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#Notes"><span class="tocnumber">10</span> <span class="toctext">Notes</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a>
<ul>
<li class="toclevel-2"><a href="#Drug_information"><span class="tocnumber">11.1</span> <span class="toctext">Drug information</span></a></li>
<li class="toclevel-2"><a href="#Diagnostic_Tools"><span class="tocnumber">11.2</span> <span class="toctext">Diagnostic Tools</span></a></li>
<li class="toclevel-2"><a href="#Patient_experiences"><span class="tocnumber">11.3</span> <span class="toctext">Patient experiences</span></a></li>
</ul>
</li>
</ul>
</td>
</tr>
</table>
<script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script>
<p><a name="Indications" id="Indications"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=1" title="Edit section: Indications">edit</a>]</span> <span class="mw-headline">Indications</span></h2>
<p><a name="Approved" id="Approved"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=2" title="Edit section: Approved">edit</a>]</span> <span class="mw-headline">Approved</span></h3>
<p>Venlafaxine is used primarily for the treatment of <a href="/wiki/Major_depressive_disorder" title="Major depressive disorder">major depression</a>, <a href="/wiki/Generalized_anxiety_disorder" title="Generalized anxiety disorder">generalized anxiety disorder</a>, <a href="/wiki/Social_anxiety_disorder" title="Social anxiety disorder" class="mw-redirect">social anxiety disorder</a>, and <a href="/wiki/Panic_disorder" title="Panic disorder">panic disorder</a> in adults.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-0" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p><a name="Depression" id="Depression"></a></p>
<h4><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=3" title="Edit section: Depression">edit</a>]</span> <span class="mw-headline">Depression</span></h4>
<p>Venlafaxine was shown to be effective for depression in multiple double blind studies. Venlafaxine is similar in efficacy to the <a href="/wiki/Tricyclic_antidepressants" title="Tricyclic antidepressants" class="mw-redirect">tricyclic antidepressants</a> <a href="/wiki/Amitriptyline" title="Amitriptyline">amitriptyline</a> (Elavil) and <a href="/wiki/Imipramine" title="Imipramine">imipramine</a> and it was better tolerated than amitriptyline. Venlafaxine appears to have efficacy similar or somewhat better than <a href="/wiki/Sertraline" title="Sertraline">sertraline</a> (Zoloft) and <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> (Prozac) depending on the criteria and rating scales used. In particular, higher doses of venlafaxine are more effective, and more patients achieved <a href="/wiki/Remission" title="Remission">remission</a> or were "very much improved". At the same time the efficacy was similar if the number of patients who achieved "response" or were "improved" was considered. A <a href="/wiki/Meta-analysis" title="Meta-analysis">meta-analysis</a> comparing venlafaxine and combined groups of <a href="/wiki/SSRI" title="SSRI" class="mw-redirect">SSRI</a> or tricyclic antidepressants indicated superiority of venlafaxine.<sup id="cite_ref-pmid11098413_2-0" class="reference"><a href="#cite_note-pmid11098413-2" title=""><span>[</span>3<span>]</span></a></sup> Based on the same set of criteria, venlafaxine was similar in efficacy to an atypical antidepressant <a href="/wiki/Bupropion" title="Bupropion">bupropion</a> (Wellbutrin); however, the remission rate was significantly lower for venlafaxine.<sup id="cite_ref-pmid16974189_3-0" class="reference"><a href="#cite_note-pmid16974189-3" title=""><span>[</span>4<span>]</span></a></sup> Venlafaxine was also marginally inferior in efficacy to a newer SSRI <a href="/wiki/Escitalopram" title="Escitalopram">escitalopram</a> (Lexapro) and had twice higher frequency of the side effects, in particular, nausea, ejaculation disorder, somnolence and sweating.<sup id="cite_ref-pmid15367045_4-0" class="reference"><a href="#cite_note-pmid15367045-4" title=""><span>[</span>5<span>]</span></a></sup> In a double-blind study, patients who did not respond to an SSRI were switched to venlafaxine or <a href="/wiki/Citalopram" title="Citalopram">citalopram</a>. Similar improvement was observed in both groups.<sup id="cite_ref-pmid18408525_5-0" class="reference"><a href="#cite_note-pmid18408525-5" title=""><span>[</span>6<span>]</span></a></sup></p>
<p>A popular magazine <i><a href="/wiki/Consumer_Reports" title="Consumer Reports">Consumer Reports</a></i>, which in 2004 had rated venlafaxine as the most effective among six commonly prescribed antidepressants,<sup id="cite_ref-6" class="reference"><a href="#cite_note-6" title=""><span>[</span>7<span>]</span></a></sup> no longer recommends it. <a href="/wiki/Fluoxetine" title="Fluoxetine">Fluoxetine</a>, <a href="/wiki/Citalopram" title="Citalopram">citalopram</a> and <a href="/wiki/Bupropion" title="Bupropion">bupropion</a> have been chosen as Consumer Reports Best Buy drugs in the updated version of their guide, based upon effectiveness, safety, side effects, and cost.<sup id="cite_ref-7" class="reference"><a href="#cite_note-7" title=""><span>[</span>8<span>]</span></a></sup></p>
<p><a name="Off-label_.2F_investigational_uses" id="Off-label_.2F_investigational_uses"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=4" title="Edit section: Off-label / investigational uses">edit</a>]</span> <span class="mw-headline">Off-label / investigational uses</span></h3>
<p>Many doctors are starting to prescribe venlafaxine "off label" for the treatment of <a href="/wiki/Diabetic_neuropathy" title="Diabetic neuropathy">diabetic neuropathy</a> (in a similar manner to <a href="/wiki/Duloxetine" title="Duloxetine">duloxetine</a>) and <a href="/wiki/Migraine" title="Migraine">migraine</a> prophylaxis (in some people, however, venlafaxine can exacerbate or cause migraines). Studies have shown venlafaxine's effectiveness for these conditions.<sup id="cite_ref-8" class="reference"><a href="#cite_note-8" title=""><span>[</span>9<span>]</span></a></sup><sup id="cite_ref-9" class="reference"><a href="#cite_note-9" title=""><span>[</span>10<span>]</span></a></sup> It has also been found to reduce the severity of 'hot-flashes' in <a href="/wiki/Menopause" title="Menopause">menopausal</a> women.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10" title=""><span>[</span>11<span>]</span></a></sup><sup id="cite_ref-11" class="reference"><a href="#cite_note-11" title=""><span>[</span>12<span>]</span></a></sup></p>
<p>Substantial weight loss in patients with major depression, generalized anxiety disorder, and social phobia has been noted, but the manufacturer does not recommend use as an <a href="/wiki/Anorectic" title="Anorectic">anorectic</a> either alone or in combination with phentermine or other amphetamine-like drugs.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-1" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup> Venlafaxine hydrochloride is in the phenethylamine class of modern chemicals, which includes amphetamine, methylendioxymethamphetamine (MDMA), and methamphetamine. This chemical structure likely lends to its activating properties, however some patients find Venlafaxine highly sedating despite its more common stimulatory effects.</p>
<p>Venlafaxine is not approved for the treatment of depressive phases of <a href="/wiki/Bipolar_disorder" title="Bipolar disorder">bipolar disorder</a>; this has some potential danger as venlafaxine can induce <a href="/wiki/Mania" title="Mania">mania</a>, <a href="/wiki/Mixed_state_(psychology)" title="Mixed state (psychology)" class="mw-redirect">mixed states</a>, rapid cycling and/or <a href="/wiki/Psychosis" title="Psychosis">psychosis</a> in some bipolar patients, particularly if they are not also being treated with a <a href="/wiki/Mood_stabilizer" title="Mood stabilizer">mood stabilizer</a>.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-2" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p>Due to its action on both the serotoninergic and <a href="/wiki/Adrenergic" title="Adrenergic">adrenergic</a> systems, Venlafaxine is also used as a treatment to reduce episodes of <a href="/wiki/Cataplexy" title="Cataplexy">cataplexy</a>, a form of muscle weakness, in patients with the <a href="/wiki/Sleep_disorder" title="Sleep disorder">sleep disorder</a> <a href="/wiki/Narcolepsy" title="Narcolepsy">narcolepsy</a>.<sup id="cite_ref-12" class="reference"><a href="#cite_note-12" title=""><span>[</span>13<span>]</span></a></sup></p>
<p>Venlafaxine was found in one study to be equal to <a href="/wiki/Anafranil" title="Anafranil" class="mw-redirect">Anafranil</a> in the treatment of <a href="/wiki/OCD" title="OCD" class="mw-redirect">OCD</a> with fewer side effects.<sup id="cite_ref-pmid12444814_13-0" class="reference"><a href="#cite_note-pmid12444814-13" title=""><span>[</span>14<span>]</span></a></sup></p>
<p>Due to its tendency to increase blood pressure and its modulative effects on the <a href="/wiki/Autonomic_Nervous_System" title="Autonomic Nervous System" class="mw-redirect">autonomic nervous system</a>, venlafaxine is often used to treat <a href="/wiki/Orthostatic_intolerance" title="Orthostatic intolerance">orthostatic intolerance</a> and <a href="/wiki/Postural_orthostatic_tachycardia_syndrome" title="Postural orthostatic tachycardia syndrome">postural orthostatic tachycardia syndrome</a>.<sup id="cite_ref-14" class="reference"><a href="#cite_note-14" title=""><span>[</span>15<span>]</span></a></sup></p>
<p><a name="Contraindications" id="Contraindications"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=5" title="Edit section: Contraindications">edit</a>]</span> <span class="mw-headline">Contraindications</span></h2>
<p>Venlafaxine is not recommended in patients <a href="/wiki/Hypersensitivity" title="Hypersensitivity">hypersensitive</a> to venlafaxine. It should not be taken by anyone who is allergic to the inactive ingredients, which include <a href="/wiki/Gelatin" title="Gelatin">gelatin</a>, <a href="/wiki/Cellulose" title="Cellulose">cellulose</a>, ethylcellulose, <a href="/wiki/Iron_oxide" title="Iron oxide">iron oxide</a>, <a href="/wiki/Titanium_dioxide" title="Titanium dioxide">titanium dioxide</a> and <a href="/wiki/Hypromellose" title="Hypromellose">hypromellose</a>. It should never be used in conjunction with a <a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">monoamine oxidase inhibitor</a> (MAOI), due to the potential to develop a potentially deadly condition known as <a href="/wiki/Serotonin_syndrome" title="Serotonin syndrome">serotonin syndrome</a>. At least 14 days time lag are required between the intake of venlafaxine and MAO inhibitors. Caution should also be used in those with a seizure disorder. Venlafaxine is not approved for use in children or adolescents.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-3" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup> However, Wyeth does provide information on precautions if venlafaxine is prescribed to this age group for the treatment of non-approved conditions. Studies in these age groups have not established its efficacy or safety.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15" title=""><span>[</span>16<span>]</span></a></sup></p>
<p><a name="Glaucoma" id="Glaucoma"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=6" title="Edit section: Glaucoma">edit</a>]</span> <span class="mw-headline">Glaucoma</span></h3>
<p>Venlafaxine can increase eye pressure, so those with <a href="/wiki/Glaucoma" title="Glaucoma">glaucoma</a> may require more frequent eye checks.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-4" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p><a name="Pregnancy.2C_labor.2C_and_delivery" id="Pregnancy.2C_labor.2C_and_delivery"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=7" title="Edit section: Pregnancy, labor, and delivery">edit</a>]</span> <span class="mw-headline">Pregnancy, labor, and delivery</span></h3>
<p>There are no adequate and well controlled studies with venlafaxine in pregnant women. Therefore, venlafaxine should only be used during pregnancy if clearly needed.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-5" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup> Prospective studies have not shown any statistically significant <a href="/wiki/Congenital_disorder" title="Congenital disorder">congenital malformations</a>.<sup id="cite_ref-16" class="reference"><a href="#cite_note-16" title=""><span>[</span>17<span>]</span></a></sup> There have, however, been some reports of self-limiting effects on newborn infants.<sup id="cite_ref-17" class="reference"><a href="#cite_note-17" title=""><span>[</span>18<span>]</span></a></sup> As with other Serotonin Reuptake Inhibitors, these effects are generally short, lasting only 3 to 5 days<sup id="cite_ref-18" class="reference"><a href="#cite_note-18" title=""><span>[</span>19<span>]</span></a></sup> and rarely resulting in severe complications.<sup id="cite_ref-pmid15900008_19-0" class="reference"><a href="#cite_note-pmid15900008-19" title=""><span>[</span>20<span>]</span></a></sup> Use of Venlafaxine in pregnancy (like other Serotonin Reuptake Inhibitors) should be considered on a case-by-case basis.</p>
<p><a name="Heart_disease_and_hypertension" id="Heart_disease_and_hypertension"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=8" title="Edit section: Heart disease and hypertension">edit</a>]</span> <span class="mw-headline">Heart disease and hypertension</span></h3>
<p>The FDA has asked the sponsors of all SNRIs to include the potential risk for persistent <a href="/wiki/Pulmonary_hypertension" title="Pulmonary hypertension">pulmonary hypertension</a> (PPHN) in prescribing data as of July 19, 2006. Medications containing Venlafaxine caused a mean heart rate increase of 4 b.p.m. in clinical trials, along with a sustained increase in blood pressure in some.</p>
<p><a name="Adverse_effects" id="Adverse_effects"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=9" title="Edit section: Adverse effects">edit</a>]</span> <span class="mw-headline">Adverse effects</span></h2>
<p><a name="Suicide_ideation.2Frisk" id="Suicide_ideation.2Frisk"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=10" title="Edit section: Suicide ideation/risk">edit</a>]</span> <span class="mw-headline">Suicide ideation/risk</span></h3>
<p>The US Food and Drug Administration body (FDA) requires all antidepressants, including venlafaxine, to carry a black box with a generic warning about a possible suicide risk. In addition, the most recent research indicated that patients taking venlafaxine are at increased risk of suicide.</p>
<p>A study conducted in Finland followed more than 15,000 patients for 3.4 years. Venlafaxine increased suicide risk 1.6-fold (statistically significant), as compared to no treatment. At the same time, <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> (Prozac) halved the suicide risk.<sup id="cite_ref-pmid17146010_20-0" class="reference"><a href="#cite_note-pmid17146010-20" title=""><span>[</span>21<span>]</span></a></sup></p>
<p>In another study, the data on more than 200,000 cases was obtained from the UK general practice research database. The patients taking venlafaxine had significantly higher risk of completed suicide than the ones on <a href="/wiki/Fluoxetine" title="Fluoxetine">fluoxetine</a> (Prozac) (2.8 times) or <a href="/wiki/Citalopram" title="Citalopram">citalopram</a> (Celexa) (2.4 times). Even after taking into consideration the fact that venlafaxine was generally prescribed for more severe depression, venlafaxine was associated with 1.6-1.7 times more suicides than fluoxetine or citalopram. This difference was no longer statistically significant due to the rarity of completed suicides. However, for the attempted suicides (more frequent event) the 1.2-1.3 times higher risk for venlafaxine still stayed statistically significant after the adjustment.<sup id="cite_ref-pmid17164297_21-0" class="reference"><a href="#cite_note-pmid17164297-21" title=""><span>[</span>22<span>]</span></a></sup></p>
<p>An analysis of clinical trials by the FDA statisticians showed the incidence of suicidal behavior among the adults on venlafaxine to be not significantly different from fluoxetine or <a href="/wiki/Placebo" title="Placebo">placebo</a>.<sup id="cite_ref-FDA_22-0" class="reference"><a href="#cite_note-FDA-22" title=""><span>[</span>23<span>]</span></a></sup> A possible explanation for this discrepancy is that suicidal patients are generally excluded from clinical trials, and so clinical trials are not quite representative of the real population of patients.<sup class="noprint Template-Fact"><span title="This claim needs references to reliable sources&#160;since March 2009" style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Citation_needed" title="Wikipedia:Citation needed">citation needed</a></i>]</span></sup></p>
<p>Venlafaxine is contraindicated to children, adolescents and young adults. According to the FDA analysis of clinical trials<sup id="cite_ref-FDA_22-1" class="reference"><a href="#cite_note-FDA-22" title=""><span>[</span>23<span>]</span></a></sup> venlafaxine caused a 5-fold increase (statistically significant) of suicidal ideation and behavior in subjects younger than 25. In another analysis, venlafaxine was no better than placebo among children (7–11 years old) and improved the depression in adolescents (12–17 years old). However, in both groups hostility and suicidal behavior were increased in comparison to the placebo treatment.<sup id="cite_ref-pmid17420682_23-0" class="reference"><a href="#cite_note-pmid17420682-23" title=""><span>[</span>24<span>]</span></a></sup></p>
<p><a name="Common_side_effects" id="Common_side_effects"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=11" title="Edit section: Common side effects">edit</a>]</span> <span class="mw-headline">Common side effects</span></h3>
<p>NOTE: The percentage of occurrences for each side effect listed comes from clinical trial data provided by Wyeth Pharmaceuticals Inc. The percentages indicate the percentage of people that experienced the side effect in clinical trials.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-6" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<ul>
<li><a href="/wiki/Headache" title="Headache">Headache</a> (34%)</li>
<li><a href="/wiki/Nausea" title="Nausea">Nausea</a> (21-35%)</li>
<li><a href="/wiki/Insomnia" title="Insomnia">Insomnia</a> (15-23%)</li>
<li><a href="/wiki/Sexual_dysfunction" title="Sexual dysfunction">Sexual dysfunction</a> (14-34%)</li>
<li><a href="/wiki/Dry_mouth" title="Dry mouth" class="mw-redirect">Dry mouth</a> (12-16%)</li>
<li><a href="/wiki/Dizziness" title="Dizziness">Dizziness</a> (11-20%)</li>
<li><a href="/wiki/Sweating" title="Sweating" class="mw-redirect">Sweating</a> (10-14%)</li>
<li>Decreased Appetite (8-20%)</li>
<li>Abnormal ejaculation (8-16%)</li>
<li><a href="/wiki/Hypertension" title="Hypertension">Hypertension</a> (4-5%)</li>
<li>Vivid/Abnormal <a href="/wiki/Dream" title="Dream">dreams</a> (3-7%)</li>
<li><a href="/wiki/Akathisia" title="Akathisia">Akathisia</a> (Agitation) (3-4%)</li>
<li>Decreased libido (3-9%)</li>
<li>Increased yawning (3-5%)</li>
<li><a href="/wiki/Apathy" title="Apathy">Apathy</a></li>
<li><a href="/wiki/Constipation" title="Constipation">Constipation</a></li>
<li>Ongoing <a href="/wiki/Irritable_Bowel_Syndrome" title="Irritable Bowel Syndrome" class="mw-redirect">Irritable Bowel Syndrome</a></li>
<li><a href="/wiki/Fatigue_(physical)" title="Fatigue (physical)" class="mw-redirect">Fatigue</a></li>
<li><a href="/wiki/Vertigo_(medical)" title="Vertigo (medical)">Vertigo</a></li>
<li><a href="/wiki/Orthostatic_hypotension" title="Orthostatic hypotension">Orthostatic hypotension</a> (postural drop in blood pressure)</li>
<li>Impulsive Actions</li>
<li>Electric shock-like sensations also called "<a href="/wiki/Brain_zaps" title="Brain zaps" class="mw-redirect">Brain zaps</a>"</li>
<li>Increased anxiety at the start of treatment</li>
<li>Memory Loss</li>
<li><a href="/wiki/Restless_Legs_Syndrome" title="Restless Legs Syndrome" class="mw-redirect">Restless Legs Syndrome</a></li>
</ul>
<p><a name="Less_common_to_rare_side-effects" id="Less_common_to_rare_side-effects"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=12" title="Edit section: Less common to rare side-effects">edit</a>]</span> <span class="mw-headline">Less common to rare side-effects</span></h3>
<p>Note 'Rare' adverse effects occur in fewer than 1 in 1000 patients. 'Infrequent' adverse effects occur in 1 in 100 to 1 in 1000 patients.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-7" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<ul>
<li><a href="/wiki/Cardiac_arrhythmia" title="Cardiac arrhythmia">Cardiac arrhythmia</a></li>
<li>Increased serum cholesterol</li>
<li>Gas or stomach pain</li>
<li>Abnormal vision</li>
<li><a href="/wiki/Akathisia" title="Akathisia">Nervousness, agitation or increased anxiety</a></li>
<li><a href="/wiki/Panic_Attack" title="Panic Attack" class="mw-redirect">Panic Attacks</a></li>
<li>Depressed feelings</li>
<li><a href="/wiki/Suicidal_ideation" title="Suicidal ideation">Suicidal thoughts</a></li>
<li>Confusion</li>
<li><a href="/wiki/Neuroleptic_malignant_syndrome" title="Neuroleptic malignant syndrome">Neuroleptic malignant syndrome</a></li>
<li>Loss of appetite</li>
<li><a href="/wiki/Tremor" title="Tremor">Tremor</a></li>
<li>Drowsiness</li>
<li>Allergic skin reactions</li>
<li>External bleeding</li>
<li>Serious <a href="/wiki/Bone_marrow" title="Bone marrow">bone marrow</a> damage (<a href="/wiki/Thrombocytopenia" title="Thrombocytopenia">thrombocytopenia</a>, <a href="/wiki/Agranulocytosis" title="Agranulocytosis">agranulocytosis</a>)</li>
<li><a href="/wiki/Hepatitis" title="Hepatitis">Hepatitis</a></li>
<li><a href="/wiki/Pancreatitis" title="Pancreatitis">Pancreatitis</a></li>
<li><a href="/wiki/Seizure" title="Seizure">Seizure</a></li>
<li><a href="/wiki/Tardive_dyskinesia" title="Tardive dyskinesia">Tardive dyskinesia</a></li>
<li>Difficulty swallowing</li>
<li>Psychosis</li>
<li>Hair Loss</li>
<li>Hostility</li>
<li>Activation of mania/hypomania.</li>
<li>Weight Loss (of concern when treating patients suffering from <a href="/wiki/Anorexia_nervosa" title="Anorexia nervosa">anorexia nervosa</a>)</li>
<li>Weight gain (effect not clear, but of concern when treating people who may have <a href="/wiki/Body_Dysmorphic_Disorder" title="Body Dysmorphic Disorder" class="mw-redirect">Body Dysmorphic Disorder</a>).</li>
<li>Homicidal Thoughts</li>
<li>Aggression</li>
<li><a href="/wiki/Depersonalization" title="Depersonalization">Depersonalization</a></li>
<li>Visual Hallucinations</li>
<li>Swollen and/or bleeding gums</li>
<li>Frequent urination</li>
</ul>
<p><a name="Dose_dependency_of_adverse_events" id="Dose_dependency_of_adverse_events"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=13" title="Edit section: Dose dependency of adverse events">edit</a>]</span> <span class="mw-headline">Dose dependency of adverse events</span></h3>
<p>A comparison of adverse event rates in a fixed-dose study comparing venlafaxine 75, 225, and 375&#160;mg/day with <a href="/wiki/Placebo" title="Placebo">placebo</a> revealed a dose dependency for some of the more common adverse events associated with venlafaxine use. The rule for including events was to enumerate those that occurred at an incidence of 5% or more for at least one of the venlafaxine groups and for which the incidence was at least twice the placebo incidence for at least one venlafaxine group. Tests for potential dose relationships for these events (Cochran-Armitage Test, with a criterion of exact 2-sided p-value &lt;=0.05) suggested a dose-dependency for several adverse events in this list, including chills, hypertension, anorexia, nausea, agitation, dizziness, somnolence, tremor, yawning, sweating, and abnormal ejaculation.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-8" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p><a name="Memory_Loss" id="Memory_Loss"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=14" title="Edit section: Memory Loss">edit</a>]</span> <span class="mw-headline">Memory Loss</span></h3>
<p>In a study comparing the tolerability of venlafaxine at standard doses, ranging from 75 to 300&#160;mg, against relatively high doses (rarely prescribed), ranging from 375 to 600&#160;mg per day, for treating DSM-IV major depressive disorder "failing memory" was reported in 44% of cases. The severity of venlafaxine-induced memory loss was also noted to increase with dose and length of treatment.<sup id="cite_ref-pmid15260908_24-0" class="reference"><a href="#cite_note-pmid15260908-24" title=""><span>[</span>25<span>]</span></a></sup></p>
<p><a name="Discontinuation_Syndrome" id="Discontinuation_Syndrome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=15" title="Edit section: Discontinuation Syndrome">edit</a>]</span> <span class="mw-headline">Discontinuation Syndrome</span></h3>
<div class="rellink noprint relarticle mainarticle">Main article: <a href="/wiki/Discontinuation_of_Venlafaxine" title="Discontinuation of Venlafaxine" class="mw-redirect">Discontinuation of Venlafaxine</a></div>
<p>In vitro studies revealed that venlafaxine has virtually no affinity for opiate, benzodiazepine, phencyclidine (<a href="/wiki/PCP" title="PCP">PCP</a>), or N-methyl-D-aspartic acid (<a href="/wiki/NMDA" title="NMDA">NMDA</a>) receptors. It has no significant CNS stimulant activity in rodents. In primate drug discrimination studies, venlafaxine showed no significant stimulant or depressant abuse liability.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-9" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup></p>
<p>Notwithstanding these findings, some patients stopping venlafaxine use experience <a href="/wiki/SSRI_discontinuation_syndrome" title="SSRI discontinuation syndrome">SSRI discontinuation syndrome</a> . This is especially noted if a patient misses a dose, but can also occur when reduction of dosage is done with a doctor's care. The high risk of discontinuation syndrome symptoms may reflect venlafaxine's short half-life.<sup id="cite_ref-pmid11347722_25-0" class="reference"><a href="#cite_note-pmid11347722-25" title=""><span>[</span>26<span>]</span></a></sup> Missing even a single dose can induce discontinuation effects in some patients.<sup id="cite_ref-ANZ_JPsych1998-parker_26-0" class="reference"><a href="#cite_note-ANZ_JPsych1998-parker-26" title=""><span>[</span>27<span>]</span></a></sup> Discontinuation is similar in nature to those of SSRIs such as <a href="/wiki/Paroxetine" title="Paroxetine">Paroxetine</a> (<a href="/wiki/Paxil" title="Paxil" class="mw-redirect">Paxil</a> or <a href="/wiki/Seroxat" title="Seroxat" class="mw-redirect">Seroxat</a>). Sudden discontinuation of venlafaxine seems to cause particularly severe discontinuation symptoms.<sup id="cite_ref-AmJPsych1997-fava_27-0" class="reference"><a href="#cite_note-AmJPsych1997-fava-27" title=""><span>[</span>28<span>]</span></a></sup> As reported in 2001 by Haddad in the journal <i>Drug Safety</i>, "another strategy to consider is switching to fluoxetine, which may suppress the discontinuation symptoms, but which has little tendency to cause such symptoms itself," and then discontinuing that.<sup id="cite_ref-pmid11347722_25-1" class="reference"><a href="#cite_note-pmid11347722-25" title=""><span>[</span>26<span>]</span></a></sup></p>
<p>Although many other drugs can cause withdrawal symptoms which are not associated with addiction or dependence, for example, <a href="/wiki/Anticonvulsants" title="Anticonvulsants" class="mw-redirect">anticonvulsants</a>, <a href="/wiki/Beta-blockers" title="Beta-blockers" class="mw-redirect">beta-blockers</a>, nitrates, <a href="/wiki/Diuretic" title="Diuretic">diuretics</a>, centrally acting antihypertensives, <a href="/wiki/Sympathomimetic" title="Sympathomimetic" class="mw-redirect">sympathomimetics</a>, <a href="/wiki/Heparin" title="Heparin">heparin</a>, <a href="/wiki/Tamoxifen" title="Tamoxifen">tamoxifen</a>, dopaminergic agents, <a href="/wiki/Antipsychotics" title="Antipsychotics" class="mw-redirect">antipsychotics</a>, and <a href="/wiki/Lithium_pharmacology" title="Lithium pharmacology">lithium</a>,<sup id="cite_ref-pmid11347722_25-2" class="reference"><a href="#cite_note-pmid11347722-25" title=""><span>[</span>26<span>]</span></a></sup> addiction or dependence is a more common effect described for drugs that (are thought to, or may) improve mental well-being.<sup id="cite_ref-pmid9081020_28-0" class="reference"><a href="#cite_note-pmid9081020-28" title=""><span>[</span>29<span>]</span></a></sup></p>
<p><a name="Serotonin_syndrome" id="Serotonin_syndrome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=16" title="Edit section: Serotonin syndrome">edit</a>]</span> <span class="mw-headline">Serotonin syndrome</span></h3>
<p>The development of a potentially life-threatening <a href="/wiki/Serotonin_syndrome" title="Serotonin syndrome">serotonin syndrome</a> (also more recently classified as "serotonin toxicity")<sup id="cite_ref-Dunkley_29-0" class="reference"><a href="#cite_note-Dunkley-29" title=""><span>[</span>30<span>]</span></a></sup> may occur with Venlafaxine treatment, particularly with concomitant use of serotonergic drugs (including <a href="/wiki/SSRI" title="SSRI" class="mw-redirect">SSRIs</a>, <a href="/wiki/SNRI" title="SNRI">SNRIs</a>, and triptans) and with drugs that impair metabolism of serotonin (including <a href="/wiki/MAOI" title="MAOI" class="mw-redirect">MAOIs</a>). Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Venlafaxine-induced serotonin syndrome has also been reported when venlafxine has been taken in isolation in overdose.<sup id="cite_ref-Kolecki_30-0" class="reference"><a href="#cite_note-Kolecki-30" title=""><span>[</span>31<span>]</span></a></sup> An abortive serotonin syndrome state, in which some but not all of the symptoms of the full serotonin syndrome are present, has been reported with venlafaxine at mid-range dosages (150&#160;mg per day)<sup id="cite_ref-31" class="reference"><a href="#cite_note-31" title=""><span>[</span>32<span>]</span></a></sup> A case of a patient with serotonin syndrome induced by low-dose venlafaxine (37.5&#160;mg per day) has also been reported.<sup id="cite_ref-pmid12549949_32-0" class="reference"><a href="#cite_note-pmid12549949-32" title=""><span>[</span>33<span>]</span></a></sup></p>
<p><a name="Combined_Serotonin_Toxicity_and_SSRI_Discontinuation_Syndrome" id="Combined_Serotonin_Toxicity_and_SSRI_Discontinuation_Syndrome"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=17" title="Edit section: Combined Serotonin Toxicity and SSRI Discontinuation Syndrome">edit</a>]</span> <span class="mw-headline">Combined Serotonin Toxicity and SSRI Discontinuation Syndrome</span></h3>
<p>Venlafaxine may be particularly hazardous to those individuals who are susceptible to both venlafaxine-induced serotonin toxicity (also known as <a href="/wiki/Serotonin_syndrome" title="Serotonin syndrome">serotonin syndrome</a>) and <a href="/wiki/SSRI_discontinuation_syndrome" title="SSRI discontinuation syndrome">SSRI discontinuation syndrome</a>. In such cases individuals who have developed the potentially fatal serotonin toxicity and/or may be at risk of doing so may find cessation or dose reduction unachievable placing them at continuing risk. As it is not possible to determine which patients are likely to develop the most severe symptoms of the discontinuation syndrome before cessation or dose reduction is attempted, this dual risk requires that all patients are closely monitored during any increase in dosage (when the patient is most at risk of developing serotonin toxicity)<sup id="cite_ref-33" class="reference"><a href="#cite_note-33" title=""><span>[</span>34<span>]</span></a></sup> and that such increases are carried out in the smallest incremental steps possible. Additionally, patients who recommence venlafaxine or revert to a higher dosage following a failed attempt to discontinue the drug or reduce dosage are another group with an increased risk of developing serotonin toxicity.<sup id="cite_ref-pmid9081020_28-1" class="reference"><a href="#cite_note-pmid9081020-28" title=""><span>[</span>29<span>]</span></a></sup></p>
<p><a name="Available_forms" id="Available_forms"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=18" title="Edit section: Available forms">edit</a>]</span> <span class="mw-headline">Available forms</span></h2>
<div class="thumb tright">
<div class="thumbinner" style="width:152px;"><a href="/wiki/File:EffexorXR_75and150mg.png" class="image" title="Effexor XR 75 mg and 150 mg capsules"><img alt="" src="http://upload.wikimedia.org/wikipedia/commons/thumb/f/fb/EffexorXR_75and150mg.png/150px-EffexorXR_75and150mg.png" width="150" height="168" border="0" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify"><a href="/wiki/File:EffexorXR_75and150mg.png" class="internal" title="Enlarge"><img src="/skins-1.5/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
<i>Effexor XR</i> 75 mg and 150 mg capsules</div>
</div>
</div>
<p>Effexor is distributed in pentagon-shaped peach-colored tablets of 25&#160;mg, 37.5&#160;mg, 50&#160;mg, 75&#160;mg, and 100&#160;mg. There is also an extended-release version distributed in capsules of 37.5&#160;mg (gray/peach), 75&#160;mg (peach), and 150&#160;mg (brownish red).</p>
<p><a name="Venlafaxine_extended_release_.28XR.29" id="Venlafaxine_extended_release_.28XR.29"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=19" title="Edit section: Venlafaxine extended release (XR)">edit</a>]</span> <span class="mw-headline">Venlafaxine extended release (XR)</span></h3>
<p>Venlafaxine extended release is chemically the same as normal venlafaxine. The extended release version (sometimes referred to as controlled release) controls the release of the drug into the <a href="/wiki/Gastrointestinal_tract" title="Gastrointestinal tract">gastrointestinal tract</a> over a longer period than normal venlafaxine. This results in a lower peak plasma concentration. Studies have shown that the extended release formula has a lower incidence of patients suffering from <a href="/wiki/Nausea" title="Nausea">nausea</a> as a side effect resulting in a lower number of patients stopping their treatment due to <a href="/wiki/Nausea" title="Nausea">nausea</a>.<sup id="cite_ref-34" class="reference"><a href="#cite_note-34" title=""><span>[</span>35<span>]</span></a></sup> In Australia, New Zealand and Switzerland, <a href="/wiki/Wyeth" title="Wyeth">Wyeth</a> sells their venlafaxine XR tablets under the name "Efexor-XR" (note the spelling with one 'f', rather than "Effexor-XR"). In Brazil Medley sells a venlafaxine XR capsule under the brand name Alenthus XR. In September 2008, Osmotica Pharmaceuticals began marketing venlafaxine extended release tablets in the United States to compete with Wyeth's capsule-form, Effexor-XR.</p>
<p><a name="Generic" id="Generic"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=20" title="Edit section: Generic">edit</a>]</span> <span class="mw-headline">Generic</span></h3>
<p>Generic venlafaxine is available in the <a href="/wiki/United_States" title="United States">United States</a> as of August 2006 and in Canada as of December 2006. Generic forms of the extended-release version have been available in Canada as of January 2007 and currently include Co Venlafaxine XR (Cobalt Pharmaceuticals Inc.), Gen-Venlafaxine XR (Genpharm), Riva-Venlafaxine XR (Laboratoire Riva Inc.), Novo Venlafaxine XR (Novopharm Limited), PMS-Venlafaxine XR (Pharmascience Inc.), Ratio-Venlafaxine XR (ratiopharm), and Sandoz Venlafaxine XR (Sandoz Canada Inc.). Generic extended-release venlafaxine will become available in the United States in 2010.<sup id="cite_ref-35" class="reference"><a href="#cite_note-35" title=""><span>[</span>36<span>]</span></a></sup> Generic versions of both drug forms are available now in India. Generic versions are also available in the UK such as Vaxalin manufactured by RatioPharm GmbH. <a href="http://www.mhra.gov.uk/home/groups/l-reg/documents/licensing/con025694.pdf" class="external autonumber" title="http://www.mhra.gov.uk/home/groups/l-reg/documents/licensing/con025694.pdf" rel="nofollow">[1]</a></p>
<p><a name="Overdose" id="Overdose"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=21" title="Edit section: Overdose">edit</a>]</span> <span class="mw-headline">Overdose</span></h2>
<p>Most patients overdosing with venlafaxine develop only mild symptoms. However, severe toxicity is reported with the most common symptoms being <a href="/wiki/CNS_depression" title="CNS depression" class="mw-redirect">CNS depression</a>, serotonin toxicity, <a href="/wiki/Seizure" title="Seizure">seizure</a>, or <a href="/wiki/Cardiac_electrophysiology" title="Cardiac electrophysiology">cardiac conduction</a> abnormalities.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36" title=""><span>[</span>37<span>]</span></a></sup> Venlafaxine's toxicity appears to be higher than other SSRIs, with a fatal toxic dose closer to that of the <a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">tricyclic antidepressants</a> than the SSRIs. Doses of 900&#160;mg or more are likely to cause moderate toxicity.<sup id="cite_ref-QJM2003-Whyte_37-0" class="reference"><a href="#cite_note-QJM2003-Whyte-37" title=""><span>[</span>38<span>]</span></a></sup> Deaths have been reported following very large doses.<sup id="cite_ref-Pharmacotherapy2003-Mazur_38-0" class="reference"><a href="#cite_note-Pharmacotherapy2003-Mazur-38" title=""><span>[</span>39<span>]</span></a></sup><sup id="cite_ref-39" class="reference"><a href="#cite_note-39" title=""><span>[</span>40<span>]</span></a></sup></p>
<p>On May 31 2006, The <a href="/wiki/Medicines_and_Healthcare_products_Regulatory_Agency" title="Medicines and Healthcare products Regulatory Agency">Medicines and Healthcare products Regulatory Agency</a> (MHRA) UK has concluded its review into all the latest safety evidence relating to venlafaxine particularly looked at the risks associated with overdose. The advice are, the need for specialist supervision in those severely depressed or hospitalized patients who need doses 300&#160;mg or more; cardiac contra-indications are more targeted towards high risk groups; patients with uncontrolled hypertension should not take venlafaxine, and blood pressure monitoring is recommended for all patients; and updated advice on possible drug interactions.<sup id="cite_ref-40" class="reference"><a href="#cite_note-40" title=""><span>[</span>41<span>]</span></a></sup></p>
<p>On October 17, 2006 Wyeth and the FDA notified healthcare professionals of revisions to the Overdosage/Human Experience section of the prescribing information for Effexor (venlafaxine), indicated for treatment of major depressive disorder. In postmarketing experience, there have been reports of overdose with venlafaxine, occurring predominantly in combination with alcohol and/or other drugs. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcome compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Healthcare professionals are advised to prescribe Effexor and Effexor XR in the smallest quantity of capsules consistent with good patient management to reduce the risk of overdose.<sup id="cite_ref-41" class="reference"><a href="#cite_note-41" title=""><span>[</span>42<span>]</span></a></sup></p>
<p>A report in the <a href="/wiki/British_Medical_Journal" title="British Medical Journal" class="mw-redirect">British Medical Journal</a> in 2002 by Dr. Nicholas Buckley and colleagues at the Department of Clinical Pharmacology and Toxicology, <a href="/wiki/Canberra" title="Canberra">Canberra</a> Hospital, <a href="/wiki/Australia" title="Australia">Australia</a> studying fatal toxicity index (deaths per million prescriptions) found that venlafaxine's fatal toxicity is higher than that of other <a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">serotoninergic antidepressants</a> but it is similar to that of some of the less toxic <a href="/wiki/Tricyclic_antidepressants" title="Tricyclic antidepressants" class="mw-redirect">tricyclic antidepressants</a>. Overall they found serious toxicity could occur following venlafaxine overdose with reports of deaths, arrythmias, and seizures. They did, however, state that this type of data is open to criticism pointing out that mortality data may be influenced by previous literature and that "less toxic" drugs may be preferentially prescribed to patients at higher risk of poisoning and suicide but they are also less likely to be listed as the sole cause of death from overdose. It also assumes that drugs are taken in overdose with similar frequency and in similar amounts. They suggested "clinicians need to consider whether factors in their patients reduce or compensate for this risk before prescribing venlafaxine."<sup id="cite_ref-42" class="reference"><a href="#cite_note-42" title=""><span>[</span>43<span>]</span></a></sup></p>
<p>The February 27, 2007 Vancouver Sun reported that the BC Drug and Poison Information Centre has alerted doctors that the drug poses a significant risk of death from overdose, saying that venlafaxine "appears more toxic than it was originally hoped".<sup id="cite_ref-43" class="reference"><a href="#cite_note-43" title=""><span>[</span>44<span>]</span></a></sup> A doctor from the Department of Pharmacy Services College of Pharmacy, Medical University of South Carolina, Charleston, South Carolina, reported on the death of a 39-year-old patient with a 30 g overdose.<sup id="cite_ref-Pharmacotherapy2003-Mazur_38-1" class="reference"><a href="#cite_note-Pharmacotherapy2003-Mazur-38" title=""><span>[</span>39<span>]</span></a></sup> To put this into perspective, a patient would have to take over 66 of the infrequently prescribed 450&#160;mg high dosage pills, or 400 of the commonly prescribed 75&#160;mg pills.</p>
<p><a name="Management_of_overdosage" id="Management_of_overdosage"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=22" title="Edit section: Management of overdosage">edit</a>]</span> <span class="mw-headline">Management of overdosage</span></h3>
<p>There is no specific <a href="/wiki/Antidote" title="Antidote">antidote</a> for venlafaxine and management is generally supportive, providing treatment for the immediate symptoms. Administration of <a href="/wiki/Activated_charcoal" title="Activated charcoal" class="mw-redirect">activated charcoal</a> can prevent absorption of the drug. Monitoring of cardiac rhythm and vital signs is indicated. Seizures are managed with <a href="/wiki/Benzodiazepine" title="Benzodiazepine">benzodiazepines</a> or other anti-convulsants. <a href="/wiki/Forced_diuresis" title="Forced diuresis">Forced diuresis</a>, <a href="/wiki/Hemodialysis" title="Hemodialysis">hemodialysis</a>, <a href="/wiki/Exchange_transfusion" title="Exchange transfusion">exchange transfusion</a>, or <a href="/wiki/Hemoperfusion" title="Hemoperfusion">hemoperfusion</a> are unlikely to be of benefit in hastening the removal of venlafaxine, due to the drug's high <a href="/wiki/Volume_of_distribution" title="Volume of distribution">volume of distribution</a>.<sup id="cite_ref-44" class="reference"><a href="#cite_note-44" title=""><span>[</span>45<span>]</span></a></sup></p>
<p><a name="Mechanism_of_action" id="Mechanism_of_action"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=23" title="Edit section: Mechanism of action">edit</a>]</span> <span class="mw-headline">Mechanism of action</span></h2>
<p>Venlafaxine is a <a href="/wiki/Bicyclic" title="Bicyclic" class="mw-redirect">bicyclic</a> antidepressant, and is usually categorized as a <a href="/wiki/Serotonin-norepinephrine_reuptake_inhibitor" title="Serotonin-norepinephrine reuptake inhibitor">serotonin-norepinephrine reuptake inhibitor</a> (SNRI), but it has been referred to as a <a href="/wiki/Serotonin-norepinephrine-dopamine_reuptake_inhibitor" title="Serotonin-norepinephrine-dopamine reuptake inhibitor" class="mw-redirect">serotonin-norepinephrine-dopamine reuptake inhibitor</a>.<sup id="cite_ref-45" class="reference"><a href="#cite_note-45" title=""><span>[</span>46<span>]</span></a></sup><sup id="cite_ref-46" class="reference"><a href="#cite_note-46" title=""><span>[</span>47<span>]</span></a></sup> It works by blocking the <a href="/wiki/Monoamine_transporter" title="Monoamine transporter">transporter "reuptake" proteins</a> for key <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitters</a> affecting mood, thereby leaving more active neurotransmitters in the <a href="/wiki/Synapse" title="Synapse" class="mw-redirect">synapse</a>. The neurotransmitters affected are <a href="/wiki/Serotonin" title="Serotonin">serotonin</a> (5-hydroxytryptamine) and <a href="/wiki/Norepinephrine" title="Norepinephrine">norepinephrine</a> (noradrenaline). Additionally, in high doses it weakly inhibits the reuptake of <a href="/wiki/Dopamine" title="Dopamine">dopamine</a>,<sup id="cite_ref-CNSDrugs2001-Wellington_47-0" class="reference"><a href="#cite_note-CNSDrugs2001-Wellington-47" title=""><span>[</span>48<span>]</span></a></sup> with recent evidence showing that the <a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">norepinephrine transporter</a> also transports some <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> as well, implying that <a href="/wiki/SNRI" title="SNRI">SNRIs</a> may also increase <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> transmission. This is because <a href="/wiki/SNRI" title="SNRI">SNRIs</a> work by inhibiting reuptake, i.e. preventing the <a href="/wiki/Serotonin" title="Serotonin">serotonin</a> and norepinephrine transporters from taking their respective <a href="/wiki/Neurotransmitter" title="Neurotransmitter">neurotransmitters</a> back to their storage vesicles for later use. If the <a href="/wiki/Norepinephrine_transporter" title="Norepinephrine transporter">norepinephrine transporter</a> normally recycles some <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> too, then <a href="/wiki/SNRI" title="SNRI">SNRIs</a> will also enhance <a href="/wiki/Dopaminergic" title="Dopaminergic">dopaminergic</a> transmission. Therefore, the <a href="/wiki/Antidepressant" title="Antidepressant">antidepressant</a> effects associated with increasing norepinephrine levels may also be partly or largely due to the concurrent increase in <a href="/wiki/Dopamine" title="Dopamine">dopamine</a> (particularly in the <a href="/wiki/Prefrontal_cortex" title="Prefrontal cortex">prefrontal cortex</a>).</p>
<p><a name="Pharmacokinetics" id="Pharmacokinetics"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=24" title="Edit section: Pharmacokinetics">edit</a>]</span> <span class="mw-headline">Pharmacokinetics</span></h3>
<p>Venlafaxine is well absorbed with at least 92% of an oral dose being absorbed into systemic circulation. It is extensively metabolized in the liver via the <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a> <a href="/wiki/Isoenzyme" title="Isoenzyme" class="mw-redirect">isoenzyme</a> to O-desmethylvenlafaxine, which is just as potent a serotonin-norepinephrine reuptake inhibitor as the parent compound, meaning that the differences in metabolism between extensive and <a href="/wiki/Poor_metabolizer" title="Poor metabolizer" class="mw-redirect">poor metabolizers</a> are not clinically important in terms of efficacy. Side effects, however, are reported to be more severe in <a href="/wiki/CYP2D6" title="CYP2D6">CYP2D6</a> poor metabolizers.<sup id="cite_ref-JCPT_JClinPharmTher2006-shams_48-0" class="reference"><a href="#cite_note-JCPT_JClinPharmTher2006-shams-48" title=""><span>[</span>49<span>]</span></a></sup> Steady-state concentrations of venlafaxine and its <a href="/wiki/Metabolite" title="Metabolite">metabolite</a> are attained in the <a href="/wiki/Blood" title="Blood">blood</a> within 3 days. Therapeutic effects are usually achieved within 3 to 4 weeks. No accumulation of venlafaxine has been observed during chronic administration in healthy subjects. The primary route of excretion of venlafaxine and its metabolites is via the <a href="/wiki/Kidneys" title="Kidneys" class="mw-redirect">kidneys</a>.<sup id="cite_ref-Medicinedatasheet-Wyeth_1-10" class="reference"><a href="#cite_note-Medicinedatasheet-Wyeth-1" title=""><span>[</span>2<span>]</span></a></sup> The <a href="/wiki/Half-life" title="Half-life">half-life</a> of venlafaxine is relatively short, therefore patients are directed to adhere to a strict medication routine, avoiding missing a dose. Even a single missed dose can result in the withdrawal symptoms.<sup id="cite_ref-ANZ_JPsych1998-parker_26-1" class="reference"><a href="#cite_note-ANZ_JPsych1998-parker-26" title=""><span>[</span>27<span>]</span></a></sup></p>
<p>Carriers of the (T;T) allele of rs2032583 <sup id="cite_ref-49" class="reference"><a href="#cite_note-49" title=""><span>[</span>50<span>]</span></a></sup> SNP in the ABCB1 gene are 7x less likely to respond to Venlafaxine treatment. This genetic variant is present about two thirds of people of European descent and 80% to 90% of East Asians.</p>
<p><a name="Drug_interactions" id="Drug_interactions"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=25" title="Edit section: Drug interactions">edit</a>]</span> <span class="mw-headline">Drug interactions</span></h2>
<p>Venlafaxine should be taken with caution when using <a href="/wiki/St_John%27s_wort" title="St John's wort">St John's wort</a>.<sup id="cite_ref-50" class="reference"><a href="#cite_note-50" title=""><span>[</span>51<span>]</span></a></sup> Venlafaxine may lower the seizure threshold, and co-administration with other drugs that lower the seizure threshold such as <a href="/wiki/Bupropion" title="Bupropion">bupropion</a> and <a href="/wiki/Tramadol" title="Tramadol">tramadol</a> should be done with caution and at low doses.<sup id="cite_ref-pmid18072153_51-0" class="reference"><a href="#cite_note-pmid18072153-51" title=""><span>[</span>52<span>]</span></a></sup> Seizures have also anecdotally been reported with combination of venlafaxine and <a href="/wiki/Marijuana" title="Marijuana" class="mw-redirect">marijuana</a>.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52" title=""><span>[</span>53<span>]</span></a></sup><sup id="cite_ref-53" class="reference"><a href="#cite_note-53" title=""><span>[</span>54<span>]</span></a></sup></p>
<p>There have been false positive <a href="/wiki/Phencyclidine" title="Phencyclidine">phencyclidine</a> (PCP) results caused by Venlafaxine with certain on-site routine urine-based drug tests.<sup id="cite_ref-pmid17267806_54-0" class="reference"><a href="#cite_note-pmid17267806-54" title=""><span>[</span>55<span>]</span></a></sup><sup id="cite_ref-pmid11901076_55-0" class="reference"><a href="#cite_note-pmid11901076-55" title=""><span>[</span>56<span>]</span></a></sup></p>
<p><a name="Physical.2Fchemical_properties" id="Physical.2Fchemical_properties"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=26" title="Edit section: Physical/chemical properties">edit</a>]</span> <span class="mw-headline">Physical/chemical properties</span></h2>
<p>The <a href="/wiki/Chemical_structure" title="Chemical structure">chemical structure</a> of venlafaxine is designated (R/S)-1-[2-(dimethylamino)-1-(4 methoxyphenyl)ethyl] cyclohexanol hydrochloride or (±)-1-[a [a- (dimethylamino)methyl] p-methoxybenzyl] cyclohexanol hydrochloride and it has the <a href="/wiki/Empirical_formula" title="Empirical formula">empirical formula</a> of C<sub>17</sub>H<sub>27</sub>NO<sub>2</sub>. It is a white to off-white crystalline solid. Venlafaxine is structurally and pharmacologically related to the <a href="/wiki/Analgesic" title="Analgesic">analgesic</a> <a href="/wiki/Tramadol" title="Tramadol">tramadol</a>, but not to any of the conventional antidepressant drugs, including <a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">tricyclic antidepressants</a>, <a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">Selective serotonin reuptake inhibitors</a> (SSRI), <a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">Monoamine oxidase inhibitors</a> (MAOI), or <a href="/wiki/Reversible_inhibitor_of_monoamine_oxidase_A" title="Reversible inhibitor of monoamine oxidase A">reversible inhibitors of monoamine oxidase A</a> (RIMA).<sup id="cite_ref-QJM2003-Whyte_37-1" class="reference"><a href="#cite_note-QJM2003-Whyte-37" title=""><span>[</span>38<span>]</span></a></sup></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=27" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="/wiki/Desvenlafaxine" title="Desvenlafaxine">Desvenlafaxine</a></li>
</ul>
<p><a name="Notes" id="Notes"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=28" title="Edit section: Notes">edit</a>]</span> <span class="mw-headline">Notes</span></h2>
<div class="references-small references-column-count references-column-count-2" style="-moz-column-count:2; column-count:2;">
<ol class="references">
<li id="cite_note-0"><b><a href="#cite_ref-0" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072007/405100/article.pdf" class="external text" title="http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072007/405100/article.pdf" rel="nofollow">"Top 200 brand-name drugs by units."</a>. <i>Drug Topics, Mar 5, 2007</i><span class="printonly">. <a href="http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072007/405100/article.pdf" class="external free" title="http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072007/405100/article.pdf" rel="nofollow">http://drugtopics.modernmedicine.com/drugtopics/data/articlestandard//drugtopics/072007/405100/article.pdf</a></span><span class="reference-accessdate">. Retrieved on 2007-04-08</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Top+200+brand-name+drugs+by+units.&amp;rft.atitle=Drug+Topics%2C+Mar+5%2C+2007&amp;rft_id=http%3A%2F%2Fdrugtopics.modernmedicine.com%2Fdrugtopics%2Fdata%2Farticlestandard%2F%2Fdrugtopics%2F072007%2F405100%2Farticle.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Medicinedatasheet-Wyeth-1">^ <a href="#cite_ref-Medicinedatasheet-Wyeth_1-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-2" title=""><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-3" title=""><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-4" title=""><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-5" title=""><sup><i><b>f</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-6" title=""><sup><i><b>g</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-7" title=""><sup><i><b>h</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-8" title=""><sup><i><b>i</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-9" title=""><sup><i><b>j</b></i></sup></a> <a href="#cite_ref-Medicinedatasheet-Wyeth_1-10" title=""><sup><i><b>k</b></i></sup></a> <cite style="font-style:normal" class="web"><a href="http://www.wyeth.com/content/showlabeling.asp?id=99" class="external text" title="http://www.wyeth.com/content/showlabeling.asp?id=99" rel="nofollow">"Effexor Medicines Data Sheet"</a>. Wyeth Pharmaceuticals Inc. 2006<span class="printonly">. <a href="http://www.wyeth.com/content/showlabeling.asp?id=99" class="external free" title="http://www.wyeth.com/content/showlabeling.asp?id=99" rel="nofollow">http://www.wyeth.com/content/showlabeling.asp?id=99</a></span><span class="reference-accessdate">. Retrieved on 17 September 2006</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Effexor+Medicines+Data+Sheet&amp;rft.atitle=&amp;rft.date=2006&amp;rft.pub=Wyeth+Pharmaceuticals+Inc&amp;rft_id=http%3A%2F%2Fwww.wyeth.com%2Fcontent%2Fshowlabeling.asp%3Fid%3D99&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid11098413-2"><b><a href="#cite_ref-pmid11098413_2-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGolden_RN.2C_Nicholas_L2000">Golden RN, Nicholas L (2000). "Antidepressant efficacy of venlafaxine". <i>Depression and anxiety</i> <b>12 Suppl 1</b>: 45–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1002%2F1520-6394%282000%2912%3A1+%3C45%3A%3AAID-DA5%3E3.0.CO%3B2-5" class="external text" title="http://dx.doi.org/10.1002%2F1520-6394%282000%2912%3A1+%3C45%3A%3AAID-DA5%3E3.0.CO%3B2-5" rel="nofollow">10.1002/1520-6394(2000)12:1 &lt;45::AID-DA5&gt;3.0.CO;2-5</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11098413" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11098413">PMID 11098413</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Antidepressant+efficacy+of+venlafaxine&amp;rft.jtitle=Depression+and+anxiety&amp;rft.aulast=Golden+RN%2C+Nicholas+L&amp;rft.au=Golden+RN%2C+Nicholas+L&amp;rft.date=2000&amp;rft.volume=12+Suppl+1&amp;rft.pages=45%E2%80%939&amp;rft_id=info:doi/10.1002%2F1520-6394%282000%2912%3A1+%3C45%3A%3AAID-DA5%3E3.0.CO%3B2-5&amp;rft_id=info:pmid/11098413&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid16974189-3"><b><a href="#cite_ref-pmid16974189_3-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFThase_ME.2C_Clayton_AH.2C_Haight_BR.2C_Thompson_AH.2C_Modell_JG.2C_Johnston_JA2006">Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA (2006). "A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability". <i>Journal of clinical psychopharmacology</i> <b>26</b> (5): 482–8. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2F01.jcp.0000239790.83707.ab" class="external text" title="http://dx.doi.org/10.1097%2F01.jcp.0000239790.83707.ab" rel="nofollow">10.1097/01.jcp.0000239790.83707.ab</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16974189" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16974189">PMID 16974189</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+double-blind+comparison+between+bupropion+XL+and+venlafaxine+XR%3A+sexual+functioning%2C+antidepressant+efficacy%2C+and+tolerability&amp;rft.jtitle=Journal+of+clinical+psychopharmacology&amp;rft.aulast=Thase+ME%2C+Clayton+AH%2C+Haight+BR%2C+Thompson+AH%2C+Modell+JG%2C+Johnston+JA&amp;rft.au=Thase+ME%2C+Clayton+AH%2C+Haight+BR%2C+Thompson+AH%2C+Modell+JG%2C+Johnston+JA&amp;rft.date=2006&amp;rft.volume=26&amp;rft.issue=5&amp;rft.pages=482%E2%80%938&amp;rft_id=info:doi/10.1097%2F01.jcp.0000239790.83707.ab&amp;rft_id=info:pmid/16974189&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15367045-4"><b><a href="#cite_ref-pmid15367045_4-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBielski_RJ.2C_Ventura_D.2C_Chang_CC2004">Bielski RJ, Ventura D, Chang CC (2004). "A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder". <i>The Journal of clinical psychiatry</i> <b>65</b> (9): 1190–6. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15367045" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15367045">PMID 15367045</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A+double-blind+comparison+of+escitalopram+and+venlafaxine+extended+release+in+the+treatment+of+major+depressive+disorder&amp;rft.jtitle=The+Journal+of+clinical+psychiatry&amp;rft.aulast=Bielski+RJ%2C+Ventura+D%2C+Chang+CC&amp;rft.au=Bielski+RJ%2C+Ventura+D%2C+Chang+CC&amp;rft.date=2004&amp;rft.volume=65&amp;rft.issue=9&amp;rft.pages=1190%E2%80%936&amp;rft_id=info:pmid/15367045&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid18408525-5"><b><a href="#cite_ref-pmid18408525_5-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFLenox-Smith_AJ.2C_Jiang_Q2008">Lenox-Smith AJ, Jiang Q (2008). "Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor". <i><a href="/wiki/Int_Clin_Psychopharmacol" title="Int Clin Psychopharmacol" class="mw-redirect">Int Clin Psychopharmacol</a></i> <b>23</b> (3): 113–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:10.1097/YIC.0b013e3282f424c2 (inactive 2008-06-21). <a href="http://www.ncbi.nlm.nih.gov/pubmed/18408525" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18408525">PMID 18408525</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Venlafaxine+extended+release+versus+citalopram+in+patients+with+depression+unresponsive+to+a+selective+serotonin+reuptake+inhibitor&amp;rft.jtitle=%5B%5BInt+Clin+Psychopharmacol%5D%5D&amp;rft.aulast=Lenox-Smith+AJ%2C+Jiang+Q&amp;rft.au=Lenox-Smith+AJ%2C+Jiang+Q&amp;rft.date=2008&amp;rft.volume=23&amp;rft.issue=3&amp;rft.pages=113%E2%80%939&amp;rft_id=info:doi/10.1097%2FYIC.0b013e3282f424c2&amp;rft_id=info:pmid/18408525&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-6"><b><a href="#cite_ref-6" title="">^</a></b> <cite style="font-style:normal" class="">"Mental health, readers rate antidepressant drugs", <i>Consumer Reports</i>, September 2004</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mental+health%2C+readers+rate+antidepressant+drugs&amp;rft.jtitle=Consumer+Reports&amp;rft.date=September+2004&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-7"><b><a href="#cite_ref-7" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.crbestbuydrugs.org/PDFs/Antidepressants_update.pdf" class="external text" title="http://www.crbestbuydrugs.org/PDFs/Antidepressants_update.pdf" rel="nofollow">"Consumer Reports Best Buy Drugs. Antidepressants."</a> (PDF). Consumer Reports<span class="printonly">. <a href="http://www.crbestbuydrugs.org/PDFs/Antidepressants_update.pdf" class="external free" title="http://www.crbestbuydrugs.org/PDFs/Antidepressants_update.pdf" rel="nofollow">http://www.crbestbuydrugs.org/PDFs/Antidepressants_update.pdf</a></span><span class="reference-accessdate">. Retrieved on 2007-06-23</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Consumer+Reports+Best+Buy+Drugs.+Antidepressants.&amp;rft.atitle=&amp;rft.pub=Consumer+Reports&amp;rft_id=http%3A%2F%2Fwww.crbestbuydrugs.org%2FPDFs%2FAntidepressants_update.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-8"><b><a href="#cite_ref-8" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRowbotham_M.2C_Goli_V.2C_Kunz_N.2C_Lei_D2004">Rowbotham M, Goli V, Kunz N, Lei D (2004). "Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study". <i>Pain</i> <b>110</b> (3): 697–706. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.pain.2004.05.010" class="external text" title="http://dx.doi.org/10.1016%2Fj.pain.2004.05.010" rel="nofollow">10.1016/j.pain.2004.05.010</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15288411" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15288411">PMID 15288411</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Venlafaxine+extended+release+in+the+treatment+of+painful+diabetic+neuropathy%3A+a+double-blind%2C+placebo-controlled+study&amp;rft.jtitle=Pain&amp;rft.aulast=Rowbotham+M%2C+Goli+V%2C+Kunz+N%2C+Lei+D&amp;rft.au=Rowbotham+M%2C+Goli+V%2C+Kunz+N%2C+Lei+D&amp;rft.date=2004&amp;rft.volume=110&amp;rft.issue=3&amp;rft.pages=697%E2%80%93706&amp;rft_id=info:doi/10.1016%2Fj.pain.2004.05.010&amp;rft_id=info:pmid/15288411&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-9"><b><a href="#cite_ref-9" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFOzyalcin_S.2C_Talu_G.2C_Kiziltan_E.2C_Yucel_B.2C_Ertas_M.2C_Disci_R2005">Ozyalcin S, Talu G, Kiziltan E, Yucel B, Ertas M, Disci R (2005). "The efficacy and safety of venlafaxine in the prophylaxis of migraine". <i>Headache</i> <b>45</b> (2): 144–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1111%2Fj.1526-4610.2005.05029.x" class="external text" title="http://dx.doi.org/10.1111%2Fj.1526-4610.2005.05029.x" rel="nofollow">10.1111/j.1526-4610.2005.05029.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15705120" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15705120">PMID 15705120</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+efficacy+and+safety+of+venlafaxine+in+the+prophylaxis+of+migraine&amp;rft.jtitle=Headache&amp;rft.aulast=Ozyalcin+S%2C+Talu+G%2C+Kiziltan+E%2C+Yucel+B%2C+Ertas+M%2C+Disci+R&amp;rft.au=Ozyalcin+S%2C+Talu+G%2C+Kiziltan+E%2C+Yucel+B%2C+Ertas+M%2C+Disci+R&amp;rft.date=2005&amp;rft.volume=45&amp;rft.issue=2&amp;rft.pages=144%E2%80%9352&amp;rft_id=info:doi/10.1111%2Fj.1526-4610.2005.05029.x&amp;rft_id=info:pmid/15705120&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-10"><b><a href="#cite_ref-10" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFMayo_Clinic_staff2005">Mayo Clinic staff (2005). <a href="http://www.mayoclinic.com/invoke.cfm?id=HQ01409" class="external text" title="http://www.mayoclinic.com/invoke.cfm?id=HQ01409" rel="nofollow">"Beyond hormone therapy: Other medicines may help"</a>. <i>Hot flashes: Ease the discomfort of menopause</i>. Mayo Clinic<span class="printonly">. <a href="http://www.mayoclinic.com/invoke.cfm?id=HQ01409" class="external free" title="http://www.mayoclinic.com/invoke.cfm?id=HQ01409" rel="nofollow">http://www.mayoclinic.com/invoke.cfm?id=HQ01409</a></span><span class="reference-accessdate">. Retrieved on 19 August 2005</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Beyond+hormone+therapy%3A+Other+medicines+may+help&amp;rft.atitle=Hot+flashes%3A+Ease+the+discomfort+of+menopause&amp;rft.aulast=Mayo+Clinic+staff&amp;rft.au=Mayo+Clinic+staff&amp;rft.date=2005&amp;rft.pub=Mayo+Clinic&amp;rft_id=http%3A%2F%2Fwww.mayoclinic.com%2Finvoke.cfm%3Fid%3DHQ01409&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-11"><b><a href="#cite_ref-11" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSchober_C.2C_Ansani_N2003">Schober C, Ansani N (2003). "Venlafaxine hydrochloride for the treatment of hot flashes". <i>Ann Pharmacother</i> <b>37</b> (11): 1703–7. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1345%2Faph.1C483" class="external text" title="http://dx.doi.org/10.1345%2Faph.1C483" rel="nofollow">10.1345/aph.1C483</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14565812" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14565812">PMID 14565812</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Venlafaxine+hydrochloride+for+the+treatment+of+hot+flashes&amp;rft.jtitle=Ann+Pharmacother&amp;rft.aulast=Schober+C%2C+Ansani+N&amp;rft.au=Schober+C%2C+Ansani+N&amp;rft.date=2003&amp;rft.volume=37&amp;rft.issue=11&amp;rft.pages=1703%E2%80%937&amp;rft_id=info:doi/10.1345%2Faph.1C483&amp;rft_id=info:pmid/14565812&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-12"><b><a href="#cite_ref-12" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://med.stanford.edu/school/Psychiatry/narcolepsy/medications.html" class="external text" title="http://med.stanford.edu/school/Psychiatry/narcolepsy/medications.html" rel="nofollow">"Medications"</a>. Stanford University School of Medicine, Center for Narcolepsy. Revised 02/07/2003<span class="printonly">. <a href="http://med.stanford.edu/school/Psychiatry/narcolepsy/medications.html" class="external free" title="http://med.stanford.edu/school/Psychiatry/narcolepsy/medications.html" rel="nofollow">http://med.stanford.edu/school/Psychiatry/narcolepsy/medications.html</a></span><span class="reference-accessdate">. Retrieved on 2007-09-03</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Medications&amp;rft.atitle=&amp;rft.date=Revised+02%2F07%2F2003&amp;rft.pub=Stanford+University+School+of+Medicine%2C+Center+for+Narcolepsy&amp;rft_id=http%3A%2F%2Fmed.stanford.edu%2Fschool%2FPsychiatry%2Fnarcolepsy%2Fmedications.html&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid12444814-13"><b><a href="#cite_ref-pmid12444814_13-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFAlbert_U.2C_Aguglia_E.2C_Maina_G.2C_Bogetto_F2002">Albert U, Aguglia E, Maina G, Bogetto F (November 2002). "<a href="http://www.psychiatrist.com/privatepdf/2002/v63n11/v63n1108.pdf" class="external text" title="http://www.psychiatrist.com/privatepdf/2002/v63n11/v63n1108.pdf" rel="nofollow">Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study</a>" (PDF). <i>J Clin Psychiatry</i> <b>63</b> (11): 1004–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12444814" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12444814">PMID 12444814</a><span class="printonly">. <a href="http://www.psychiatrist.com/privatepdf/2002/v63n11/v63n1108.pdf" class="external free" title="http://www.psychiatrist.com/privatepdf/2002/v63n11/v63n1108.pdf" rel="nofollow">http://www.psychiatrist.com/privatepdf/2002/v63n11/v63n1108.pdf</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Venlafaxine+versus+clomipramine+in+the+treatment+of+obsessive-compulsive+disorder%3A+a+preliminary+single-blind%2C+12-week%2C+controlled+study&amp;rft.jtitle=J+Clin+Psychiatry&amp;rft.aulast=Albert+U%2C+Aguglia+E%2C+Maina+G%2C+Bogetto+F&amp;rft.au=Albert+U%2C+Aguglia+E%2C+Maina+G%2C+Bogetto+F&amp;rft.date=November+2002&amp;rft.volume=63&amp;rft.issue=11&amp;rft.pages=1004%E2%80%939&amp;rft_id=info:pmid/12444814&amp;rft_id=http%3A%2F%2Fwww.psychiatrist.com%2Fprivatepdf%2F2002%2Fv63n11%2Fv63n1108.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-14"><b><a href="#cite_ref-14" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFHain_T">Hain T (Revised 12/30/2007). <a href="http://www.dizziness-and-balance.com/disorders/medical/orthostatic.html" class="external text" title="http://www.dizziness-and-balance.com/disorders/medical/orthostatic.html" rel="nofollow">"Orthostatic Hypotension"</a>. www.dizziness-and-balance.com<span class="printonly">. <a href="http://www.dizziness-and-balance.com/disorders/medical/orthostatic.html" class="external free" title="http://www.dizziness-and-balance.com/disorders/medical/orthostatic.html" rel="nofollow">http://www.dizziness-and-balance.com/disorders/medical/orthostatic.html</a></span><span class="reference-accessdate">. Retrieved on 2008-03-29</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Orthostatic+Hypotension&amp;rft.atitle=&amp;rft.aulast=Hain+T&amp;rft.au=Hain+T&amp;rft.date=Revised+12%2F30%2F2007&amp;rft.pub=www.dizziness-and-balance.com&amp;rft_id=http%3A%2F%2Fwww.dizziness-and-balance.com%2Fdisorders%2Fmedical%2Forthostatic.html&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-15"><b><a href="#cite_ref-15" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFCourtney_D2004">Courtney D (2004). "Selective serotonin reuptake inhibitor and venlafaxine use in children and adolescents with major depressive disorder: a systematic review of published randomized controlled trials". <i>Can J Psychiatry</i> <b>49</b> (8): 557–63. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15453105" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15453105">PMID 15453105</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Selective+serotonin+reuptake+inhibitor+and+venlafaxine+use+in+children+and+adolescents+with+major+depressive+disorder%3A+a+systematic+review+of+published+randomized+controlled+trials&amp;rft.jtitle=Can+J+Psychiatry&amp;rft.aulast=Courtney+D&amp;rft.au=Courtney+D&amp;rft.date=2004&amp;rft.volume=49&amp;rft.issue=8&amp;rft.pages=557%E2%80%9363&amp;rft_id=info:pmid/15453105&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-16"><b><a href="#cite_ref-16" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGentile_S2005">Gentile S (2005). "The safety of newer antidepressants in pregnancy and breastfeeding". <i>Drug Saf</i> <b>28</b> (2): 137–52. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.2165%2F00002018-200528020-00005" class="external text" title="http://dx.doi.org/10.2165%2F00002018-200528020-00005" rel="nofollow">10.2165/00002018-200528020-00005</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15691224" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15691224">PMID 15691224</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+safety+of+newer+antidepressants+in+pregnancy+and+breastfeeding&amp;rft.jtitle=Drug+Saf&amp;rft.aulast=Gentile+S&amp;rft.au=Gentile+S&amp;rft.date=2005&amp;rft.volume=28&amp;rft.issue=2&amp;rft.pages=137%E2%80%9352&amp;rft_id=info:doi/10.2165%2F00002018-200528020-00005&amp;rft_id=info:pmid/15691224&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-17"><b><a href="#cite_ref-17" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFde_Moor_R.2C_Mourad_L.2C_ter_Haar_J.2C_Egberts_A2003">de Moor R, Mourad L, ter Haar J, Egberts A (2003). "[Withdrawal symptoms in a neonate following exposure to venlafaxine during pregnancy]". <i>Ned Tijdschr Geneeskd</i> <b>147</b> (28): 1370–2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12892015" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12892015">PMID 12892015</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=%5BWithdrawal+symptoms+in+a+neonate+following+exposure+to+venlafaxine+during+pregnancy%5D&amp;rft.jtitle=Ned+Tijdschr+Geneeskd&amp;rft.aulast=de+Moor+R%2C+Mourad+L%2C+ter+Haar+J%2C+Egberts+A&amp;rft.au=de+Moor+R%2C+Mourad+L%2C+ter+Haar+J%2C+Egberts+A&amp;rft.date=2003&amp;rft.volume=147&amp;rft.issue=28&amp;rft.pages=1370%E2%80%932&amp;rft_id=info:pmid/12892015&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-18"><b><a href="#cite_ref-18" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFFerreira_E.2C_Carceller_AM.2C_Agogu.C3.A9_C.2C_Martin_BZ.2C_St-Andr.C3.A9_M.2C_Francoeur_D.2C_B.C3.A9rard_A2007">Ferreira E, Carceller AM, Agogué C, Martin BZ, St-André M, Francoeur D, Bérard A (2007). "[Effects of selective serotonin reuptake inhibitors and venlafaxine during pregnancy in term and preterm neonates]". <i>Pediatrics</i> <b>119</b> (1): 52–9. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1542%2Fpeds.2006-2133" class="external text" title="http://dx.doi.org/10.1542%2Fpeds.2006-2133" rel="nofollow">10.1542/peds.2006-2133</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17200271" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17200271">PMID 17200271</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=%5BEffects+of+selective+serotonin+reuptake+inhibitors+and+venlafaxine+during+pregnancy+in+term+and+preterm+neonates%5D&amp;rft.jtitle=Pediatrics&amp;rft.aulast=Ferreira+E%2C+Carceller+AM%2C+Agogu%C3%A9+C%2C+Martin+BZ%2C+St-Andr%C3%A9+M%2C+Francoeur+D%2C+B%C3%A9rard+A&amp;rft.au=Ferreira+E%2C+Carceller+AM%2C+Agogu%C3%A9+C%2C+Martin+BZ%2C+St-Andr%C3%A9+M%2C+Francoeur+D%2C+B%C3%A9rard+A&amp;rft.date=2007&amp;rft.volume=119&amp;rft.issue=1&amp;rft.pages=52%E2%80%939&amp;rft_id=info:doi/10.1542%2Fpeds.2006-2133&amp;rft_id=info:pmid/17200271&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15900008-19"><b><a href="#cite_ref-pmid15900008_19-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMoses-Kolko_EL.2C_Bogen_D.2C_Perel_J.2C_Bregar_A.2C_Uhl_K.2C_Levin_B.2C_Wisner_KL2005">Moses-Kolko EL, Bogen D, Perel J, Bregar A, Uhl K, Levin B, Wisner KL (2005). "[Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature review and implications for clinical applications]". <i>JAMA</i> <b>293</b> (19): 2372–83. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Fjama.293.19.2372" class="external text" title="http://dx.doi.org/10.1001%2Fjama.293.19.2372" rel="nofollow">10.1001/jama.293.19.2372</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15900008" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15900008">PMID 15900008</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=%5BNeonatal+signs+after+late+in+utero+exposure+to+serotonin+reuptake+inhibitors%3A+Literature+review+and+implications+for+clinical+applications%5D&amp;rft.jtitle=JAMA&amp;rft.aulast=Moses-Kolko+EL%2C+Bogen+D%2C+Perel+J%2C+Bregar+A%2C+Uhl+K%2C+Levin+B%2C+Wisner+KL&amp;rft.au=Moses-Kolko+EL%2C+Bogen+D%2C+Perel+J%2C+Bregar+A%2C+Uhl+K%2C+Levin+B%2C+Wisner+KL&amp;rft.date=2005&amp;rft.volume=293&amp;rft.issue=19&amp;rft.pages=2372%E2%80%9383&amp;rft_id=info:doi/10.1001%2Fjama.293.19.2372&amp;rft_id=info:pmid/15900008&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17146010-20"><b><a href="#cite_ref-pmid17146010_20-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFTiihonen_J.2C_L.C3.B6nnqvist_J.2C_Wahlbeck_K.2C_Klaukka_T.2C_Tanskanen_A.2C_Haukka_J2006">Tiihonen J, Lönnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J (2006). "Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort". <i>Arch. Gen. Psychiatry</i> <b>63</b> (12): 1358–67. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1001%2Farchpsyc.63.12.1358" class="external text" title="http://dx.doi.org/10.1001%2Farchpsyc.63.12.1358" rel="nofollow">10.1001/archpsyc.63.12.1358</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17146010" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17146010">PMID 17146010</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Antidepressants+and+the+risk+of+suicide%2C+attempted+suicide%2C+and+overall+mortality+in+a+nationwide+cohort&amp;rft.jtitle=Arch.+Gen.+Psychiatry&amp;rft.aulast=Tiihonen+J%2C+L%C3%B6nnqvist+J%2C+Wahlbeck+K%2C+Klaukka+T%2C+Tanskanen+A%2C+Haukka+J&amp;rft.au=Tiihonen+J%2C+L%C3%B6nnqvist+J%2C+Wahlbeck+K%2C+Klaukka+T%2C+Tanskanen+A%2C+Haukka+J&amp;rft.date=2006&amp;rft.volume=63&amp;rft.issue=12&amp;rft.pages=1358%E2%80%9367&amp;rft_id=info:doi/10.1001%2Farchpsyc.63.12.1358&amp;rft_id=info:pmid/17146010&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17164297-21"><b><a href="#cite_ref-pmid17164297_21-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFRubino_A.2C_Roskell_N.2C_Tennis_P.2C_Mines_D.2C_Weich_S.2C_Andrews_E2007">Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E (2007). "Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study". <i>BMJ</i> <b>334</b> (7587): 242. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1136%2Fbmj.39041.445104.BE" class="external text" title="http://dx.doi.org/10.1136%2Fbmj.39041.445104.BE" rel="nofollow">10.1136/bmj.39041.445104.BE</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17164297" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17164297">PMID 17164297</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Risk+of+suicide+during+treatment+with+venlafaxine%2C+citalopram%2C+fluoxetine%2C+and+dothiepin%3A+retrospective+cohort+study&amp;rft.jtitle=BMJ&amp;rft.aulast=Rubino+A%2C+Roskell+N%2C+Tennis+P%2C+Mines+D%2C+Weich+S%2C+Andrews+E&amp;rft.au=Rubino+A%2C+Roskell+N%2C+Tennis+P%2C+Mines+D%2C+Weich+S%2C+Andrews+E&amp;rft.date=2007&amp;rft.volume=334&amp;rft.issue=7587&amp;rft.pages=242&amp;rft_id=info:doi/10.1136%2Fbmj.39041.445104.BE&amp;rft_id=info:pmid/17164297&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-FDA-22">^ <a href="#cite_ref-FDA_22-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FDA_22-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="web"><a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" class="external text" title="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" rel="nofollow">"Overview for December 13 Meeting of Psychopharmacologic Drugs Advisory Committee"</a> (PDF). November 16, 2006<span class="printonly">. <a href="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" class="external free" title="http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf" rel="nofollow">http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-01-FDA.pdf</a></span><span class="reference-accessdate">. Retrieved on 2007-06-20</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Overview+for+December+13+Meeting+of+Psychopharmacologic+Drugs+Advisory+Committee&amp;rft.atitle=&amp;rft.date=November+16%2C+2006&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fohrms%2Fdockets%2Fac%2F06%2Fbriefing%2F2006-4272b1-01-FDA.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid17420682-23"><b><a href="#cite_ref-pmid17420682_23-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFEmslie_GJ.2C_Findling_RL.2C_Yeung_PP.2C_Kunz_NR.2C_Li_Y2007">Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y (2007). "Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials". <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> <b>46</b> (4): 479–88. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1097%2Fchi.0b013e31802f5f03" class="external text" title="http://dx.doi.org/10.1097%2Fchi.0b013e31802f5f03" rel="nofollow">10.1097/chi.0b013e31802f5f03</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17420682" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17420682">PMID 17420682</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Venlafaxine+ER+for+the+treatment+of+pediatric+subjects+with+depression%3A+results+of+two+placebo-controlled+trials&amp;rft.jtitle=Journal+of+the+American+Academy+of+Child+and+Adolescent+Psychiatry&amp;rft.aulast=Emslie+GJ%2C+Findling+RL%2C+Yeung+PP%2C+Kunz+NR%2C+Li+Y&amp;rft.au=Emslie+GJ%2C+Findling+RL%2C+Yeung+PP%2C+Kunz+NR%2C+Li+Y&amp;rft.date=2007&amp;rft.volume=46&amp;rft.issue=4&amp;rft.pages=479%E2%80%9388&amp;rft_id=info:doi/10.1097%2Fchi.0b013e31802f5f03&amp;rft_id=info:pmid/17420682&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid15260908-24"><b><a href="#cite_ref-pmid15260908_24-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHarrison_CL.2C_Ferrier_N.2C_Young_AH2004">Harrison CL, Ferrier N, Young AH (June 2004). "Tolerability of high-dose venlafaxine in depressed patients". <i>J. Psychopharmacol. (Oxford)</i> <b>18</b> (2): 200–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1177%2F0269881104042621" class="external text" title="http://dx.doi.org/10.1177%2F0269881104042621" rel="nofollow">10.1177/0269881104042621</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/15260908" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/15260908">PMID 15260908</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Tolerability+of+high-dose+venlafaxine+in+depressed+patients&amp;rft.jtitle=J.+Psychopharmacol.+%28Oxford%29&amp;rft.aulast=Harrison+CL%2C+Ferrier+N%2C+Young+AH&amp;rft.au=Harrison+CL%2C+Ferrier+N%2C+Young+AH&amp;rft.date=June+2004&amp;rft.volume=18&amp;rft.issue=2&amp;rft.pages=200%E2%80%934&amp;rft_id=info:doi/10.1177%2F0269881104042621&amp;rft_id=info:pmid/15260908&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid11347722-25">^ <a href="#cite_ref-pmid11347722_25-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid11347722_25-1" title=""><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-pmid11347722_25-2" title=""><sup><i><b>c</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFHaddad_PM2001">Haddad PM (2001). "Antidepressant discontinuation syndromes". <i>Drug Saf</i> <b>24</b> (3): 183–97. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.2165%2F00002018-200124030-00003" class="external text" title="http://dx.doi.org/10.2165%2F00002018-200124030-00003" rel="nofollow">10.2165/00002018-200124030-00003</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11347722" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11347722">PMID 11347722</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Antidepressant+discontinuation+syndromes&amp;rft.jtitle=Drug+Saf&amp;rft.aulast=Haddad+PM&amp;rft.au=Haddad+PM&amp;rft.date=2001&amp;rft.volume=24&amp;rft.issue=3&amp;rft.pages=183%E2%80%9397&amp;rft_id=info:doi/10.2165%2F00002018-200124030-00003&amp;rft_id=info:pmid/11347722&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-ANZ_JPsych1998-parker-26">^ <a href="#cite_ref-ANZ_JPsych1998-parker_26-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ANZ_JPsych1998-parker_26-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFParker_G.2C_Blennerhassett_J1998">Parker G, Blennerhassett J (1998). "Withdrawal reactions associated with venlafaxine". <i>Aust N Z J Psychiatry</i> <b>32</b> (2): 291–4. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.3109%2F00048679809062742" class="external text" title="http://dx.doi.org/10.3109%2F00048679809062742" rel="nofollow">10.3109/00048679809062742</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9588310" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9588310">PMID 9588310</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Withdrawal+reactions+associated+with+venlafaxine&amp;rft.jtitle=Aust+N+Z+J+Psychiatry&amp;rft.aulast=Parker+G%2C+Blennerhassett+J&amp;rft.au=Parker+G%2C+Blennerhassett+J&amp;rft.date=1998&amp;rft.volume=32&amp;rft.issue=2&amp;rft.pages=291%E2%80%934&amp;rft_id=info:doi/10.3109%2F00048679809062742&amp;rft_id=info:pmid/9588310&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-AmJPsych1997-fava-27"><b><a href="#cite_ref-AmJPsych1997-fava_27-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFFava_M.2C_Mulroy_R.2C_Alpert_J.2C_Nierenberg_A.2C_Rosenbaum_J1997">Fava M, Mulroy R, Alpert J, Nierenberg A, Rosenbaum J (1997). "Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine". <i>Am J Psychiatry</i> <b>154</b> (12): 1760–2. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9396960" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9396960">PMID 9396960</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Emergence+of+adverse+events+following+discontinuation+of+treatment+with+extended-release+venlafaxine&amp;rft.jtitle=Am+J+Psychiatry&amp;rft.aulast=Fava+M%2C+Mulroy+R%2C+Alpert+J%2C+Nierenberg+A%2C+Rosenbaum+J&amp;rft.au=Fava+M%2C+Mulroy+R%2C+Alpert+J%2C+Nierenberg+A%2C+Rosenbaum+J&amp;rft.date=1997&amp;rft.volume=154&amp;rft.issue=12&amp;rft.pages=1760%E2%80%932&amp;rft_id=info:pmid/9396960&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid9081020-28">^ <a href="#cite_ref-pmid9081020_28-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-pmid9081020_28-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFDouble_D1997">Double D (1997). "Prescribing antidepressants in general practice. People may become psychologically dependent on antidepressants". <i>BMJ</i> <b>314</b> (7083): 829. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9081020" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9081020">PMID 9081020</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Prescribing+antidepressants+in+general+practice.+People+may+become+psychologically+dependent+on+antidepressants&amp;rft.jtitle=BMJ&amp;rft.aulast=Double+D&amp;rft.au=Double+D&amp;rft.date=1997&amp;rft.volume=314&amp;rft.issue=7083&amp;rft.pages=829&amp;rft_id=info:pmid/9081020&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Dunkley-29"><b><a href="#cite_ref-Dunkley_29-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDunkley_EJ.2C_Isbister_GK.2C_Sibbritt_D.2C_Dawson_AH.2C_Whyte_IM2003">Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM (September 2003). "<a href="http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635" class="external text" title="http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635" rel="nofollow">The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity</a>". <i>QJM</i> <b>96</b> (9): 635–42. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12925718" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12925718">PMID 12925718</a><span class="printonly">. <a href="http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635" class="external free" title="http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635" rel="nofollow">http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The+Hunter+Serotonin+Toxicity+Criteria%3A+simple+and+accurate+diagnostic+decision+rules+for+serotonin+toxicity&amp;rft.jtitle=QJM&amp;rft.aulast=Dunkley+EJ%2C+Isbister+GK%2C+Sibbritt+D%2C+Dawson+AH%2C+Whyte+IM&amp;rft.au=Dunkley+EJ%2C+Isbister+GK%2C+Sibbritt+D%2C+Dawson+AH%2C+Whyte+IM&amp;rft.date=September+2003&amp;rft.volume=96&amp;rft.issue=9&amp;rft.pages=635%E2%80%9342&amp;rft_id=info:pmid/12925718&amp;rft_id=http%3A%2F%2Fwww.qjmed.oxfordjournals.org%2Fcgi%2Fcontent%2Ffull%2F96%2F9%2F635&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Kolecki-30"><b><a href="#cite_ref-Kolecki_30-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFKolecki_P1997">Kolecki P (1997). "Isolated venlafaxine-induced serotonin syndrome". <i>J Emerg Med</i> <b>15</b> (4): 491–3. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9279702" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9279702">PMID 9279702</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Isolated+venlafaxine-induced+serotonin+syndrome&amp;rft.jtitle=J+Emerg+Med&amp;rft.aulast=Kolecki+P&amp;rft.au=Kolecki+P&amp;rft.date=1997&amp;rft.volume=15&amp;rft.issue=4&amp;rft.pages=491%E2%80%933&amp;rft_id=info:pmid/9279702&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-31"><b><a href="#cite_ref-31" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFEbert_D._et_al.">Ebert D. et al.. <a href="http://www.priory.com/psych/venhall.htm" class="external text" title="http://www.priory.com/psych/venhall.htm" rel="nofollow">"Hallucinations as a side effect of venlafaxine treatment"</a>. Psychiatry On-line<span class="printonly">. <a href="http://www.priory.com/psych/venhall.htm" class="external free" title="http://www.priory.com/psych/venhall.htm" rel="nofollow">http://www.priory.com/psych/venhall.htm</a></span><span class="reference-accessdate">. Retrieved on 2008-06-17</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Hallucinations+as+a+side+effect+of+venlafaxine+treatment&amp;rft.atitle=&amp;rft.aulast=Ebert+D.+et+al.&amp;rft.au=Ebert+D.+et+al.&amp;rft.pub=Psychiatry+On-line&amp;rft_id=http%3A%2F%2Fwww.priory.com%2Fpsych%2Fvenhall.htm&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid12549949-32"><b><a href="#cite_ref-pmid12549949_32-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFPan_JJ.2C_Shen_WW2003">Pan JJ, Shen WW (February 2003). "Serotonin syndrome induced by low-dose venlafaxine". <i>Ann Pharmacother</i> <b>37</b> (2): 209–11. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12549949" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12549949">PMID 12549949</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serotonin+syndrome+induced+by+low-dose+venlafaxine&amp;rft.jtitle=Ann+Pharmacother&amp;rft.aulast=Pan+JJ%2C+Shen+WW&amp;rft.au=Pan+JJ%2C+Shen+WW&amp;rft.date=February+2003&amp;rft.volume=37&amp;rft.issue=2&amp;rft.pages=209%E2%80%9311&amp;rft_id=info:pmid/12549949&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-33"><b><a href="#cite_ref-33" title="">^</a></b> Venlafaxine (marketed as Effexor) FDA Alert: SSRIs/SNRI/Triptan and Serotonin Syndrome [issued 7/2006]</li>
<li id="cite_note-34"><b><a href="#cite_ref-34" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFDeVane_CL.2003">DeVane CL. (2003). "Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea". <i>J Clin Psychiatry</i> <b>64</b> (Suppl 18): 14–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14700450" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14700450">PMID 14700450</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Immediate-release+versus+controlled-release+formulations%3A+pharmacokinetics+of+newer+antidepressants+in+relation+to+nausea&amp;rft.jtitle=J+Clin+Psychiatry&amp;rft.aulast=DeVane+CL.&amp;rft.au=DeVane+CL.&amp;rft.date=2003&amp;rft.volume=64&amp;rft.issue=Suppl+18&amp;rft.pages=14%E2%80%939&amp;rft_id=info:pmid/14700450&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-35"><b><a href="#cite_ref-35" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWigginton2006">Wigginton, Catherine (2006-09-19), <i><a href="http://www.law.com/jsp/article.jsp?id=1158582919715" class="external text" title="http://www.law.com/jsp/article.jsp?id=1158582919715" rel="nofollow">Wyeth's Battle for Effexor Continues</a></i>, IP Law &amp; Business<span class="printonly">, <a href="http://www.law.com/jsp/article.jsp?id=1158582919715" class="external free" title="http://www.law.com/jsp/article.jsp?id=1158582919715" rel="nofollow">http://www.law.com/jsp/article.jsp?id=1158582919715</a></span><span class="reference-accessdate">, retrieved on 2007-04-25</span></cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Wyeth%27s+Battle+for+Effexor+Continues&amp;rft.aulast=Wigginton&amp;rft.aufirst=Catherine&amp;rft.au=Wigginton%2C+Catherine&amp;rft.date=2006-09-19&amp;rft.pub=IP+Law+%26+Business&amp;rft_id=http%3A%2F%2Fwww.law.com%2Fjsp%2Farticle.jsp%3Fid%3D1158582919715&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-36"><b><a href="#cite_ref-36" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBlythe_D.2C_Hackett_L1999">Blythe D, Hackett L (1999). "Cardiovascular and neurological toxicity of venlafaxine". <i>Hum Exp Toxicol</i> <b>18</b> (5): 309–13. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1191%2F096032799678840165" class="external text" title="http://dx.doi.org/10.1191%2F096032799678840165" rel="nofollow">10.1191/096032799678840165</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/10372752" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/10372752">PMID 10372752</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cardiovascular+and+neurological+toxicity+of+venlafaxine&amp;rft.jtitle=Hum+Exp+Toxicol&amp;rft.aulast=Blythe+D%2C+Hackett+L&amp;rft.au=Blythe+D%2C+Hackett+L&amp;rft.date=1999&amp;rft.volume=18&amp;rft.issue=5&amp;rft.pages=309%E2%80%9313&amp;rft_id=info:doi/10.1191%2F096032799678840165&amp;rft_id=info:pmid/10372752&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-QJM2003-Whyte-37">^ <a href="#cite_ref-QJM2003-Whyte_37-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-QJM2003-Whyte_37-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFWhyte_I.2C_Dawson_A.2C_Buckley_N2003">Whyte I, Dawson A, Buckley N (2003). "Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants". <i>QJM</i> <b>96</b> (5): 369–74. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1093%2Fqjmed%2Fhcg062" class="external text" title="http://dx.doi.org/10.1093%2Fqjmed%2Fhcg062" rel="nofollow">10.1093/qjmed/hcg062</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12702786" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12702786">PMID 12702786</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Relative+toxicity+of+venlafaxine+and+selective+serotonin+reuptake+inhibitors+in+overdose+compared+to+tricyclic+antidepressants&amp;rft.jtitle=QJM&amp;rft.aulast=Whyte+I%2C+Dawson+A%2C+Buckley+N&amp;rft.au=Whyte+I%2C+Dawson+A%2C+Buckley+N&amp;rft.date=2003&amp;rft.volume=96&amp;rft.issue=5&amp;rft.pages=369%E2%80%9374&amp;rft_id=info:doi/10.1093%2Fqjmed%2Fhcg062&amp;rft_id=info:pmid/12702786&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-Pharmacotherapy2003-Mazur-38">^ <a href="#cite_ref-Pharmacotherapy2003-Mazur_38-0" title=""><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Pharmacotherapy2003-Mazur_38-1" title=""><sup><i><b>b</b></i></sup></a> <cite style="font-style:normal" class="" id="CITEREFMazur_J.2C_Doty_J.2C_Krygiel_A2003">Mazur J, Doty J, Krygiel A (2003). "Fatality related to a 30-g venlafaxine overdose". <i>Pharmacotherapy</i> <b>23</b> (12): 1668–72. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1592%2Fphco.23.15.1668.31951" class="external text" title="http://dx.doi.org/10.1592%2Fphco.23.15.1668.31951" rel="nofollow">10.1592/phco.23.15.1668.31951</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/14695048" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/14695048">PMID 14695048</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Fatality+related+to+a+30-g+venlafaxine+overdose&amp;rft.jtitle=Pharmacotherapy&amp;rft.aulast=Mazur+J%2C+Doty+J%2C+Krygiel+A&amp;rft.au=Mazur+J%2C+Doty+J%2C+Krygiel+A&amp;rft.date=2003&amp;rft.volume=23&amp;rft.issue=12&amp;rft.pages=1668%E2%80%9372&amp;rft_id=info:doi/10.1592%2Fphco.23.15.1668.31951&amp;rft_id=info:pmid/14695048&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-39"><b><a href="#cite_ref-39" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBanham_N1998">Banham N (1998). "Fatal venlafaxine overdose". <i>Med J Aust</i> <b>169</b> (8): 445, 448. <a href="http://www.ncbi.nlm.nih.gov/pubmed/9830400" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/9830400">PMID 9830400</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Fatal+venlafaxine+overdose&amp;rft.jtitle=Med+J+Aust&amp;rft.aulast=Banham+N&amp;rft.au=Banham+N&amp;rft.date=1998&amp;rft.volume=169&amp;rft.issue=8&amp;rft.pages=445%2C+448&amp;rft_id=info:pmid/9830400&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-40"><b><a href="#cite_ref-40" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFMHRA_UK2006">MHRA UK (31 May 2006). "Updated product information for venlafaxine". <i>Safeguarding public health</i> <b>120</b>: 778. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2Fj.puhe.2006.03.006" class="external text" title="http://dx.doi.org/10.1016%2Fj.puhe.2006.03.006" rel="nofollow">10.1016/j.puhe.2006.03.006</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Updated+product+information+for+venlafaxine&amp;rft.jtitle=Safeguarding+public+health&amp;rft.aulast=MHRA+UK&amp;rft.au=MHRA+UK&amp;rft.date=31+May+2006&amp;rft.volume=120&amp;rft.pages=778&amp;rft_id=info:doi/10.1016%2Fj.puhe.2006.03.006&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-41"><b><a href="#cite_ref-41" title="">^</a></b> <cite style="font-style:normal" class="web"><a href="http://www.fda.gov/medwatch/SAFETY/2006/effexor_DHCPletter.pdf" class="external text" title="http://www.fda.gov/medwatch/SAFETY/2006/effexor_DHCPletter.pdf" rel="nofollow">"Wyeth Letter to Health Care Providers"</a> (PDF). Wyeth Pharmaceuticals Inc. 2006<span class="printonly">. <a href="http://www.fda.gov/medwatch/SAFETY/2006/effexor_DHCPletter.pdf" class="external free" title="http://www.fda.gov/medwatch/SAFETY/2006/effexor_DHCPletter.pdf" rel="nofollow">http://www.fda.gov/medwatch/SAFETY/2006/effexor_DHCPletter.pdf</a></span><span class="reference-accessdate">. Retrieved on 30 January 2007</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Wyeth+Letter+to+Health+Care+Providers&amp;rft.atitle=&amp;rft.date=2006&amp;rft.pub=Wyeth+Pharmaceuticals+Inc&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fmedwatch%2FSAFETY%2F2006%2Feffexor_DHCPletter.pdf&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-42"><b><a href="#cite_ref-42" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFBuckley_N.2C_McManus_P2002">Buckley N, McManus P (2002). "Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data". <i>BMJ</i> <b>325</b> (7376): 1332–3. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1136%2Fbmj.325.7376.1332" class="external text" title="http://dx.doi.org/10.1136%2Fbmj.325.7376.1332" rel="nofollow">10.1136/bmj.325.7376.1332</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/12468481" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/12468481">PMID 12468481</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Fatal+toxicity+of+serotoninergic+and+other+antidepressant+drugs%3A+analysis+of+United+Kingdom+mortality+data&amp;rft.jtitle=BMJ&amp;rft.aulast=Buckley+N%2C+McManus+P&amp;rft.au=Buckley+N%2C+McManus+P&amp;rft.date=2002&amp;rft.volume=325&amp;rft.issue=7376&amp;rft.pages=1332%E2%80%933&amp;rft_id=info:doi/10.1136%2Fbmj.325.7376.1332&amp;rft_id=info:pmid/12468481&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-43"><b><a href="#cite_ref-43" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREFFayerman2007">Fayerman, Pamela (February 27 2007). <a href="http://www.canada.com/vancouversun/news/story.html?id=83f35b4e-ac13-4c09-b8de-44d16750b70b&amp;k=58837" class="external text" title="http://www.canada.com/vancouversun/news/story.html?id=83f35b4e-ac13-4c09-b8de-44d16750b70b&amp;k=58837" rel="nofollow">"Warning issued over drug"</a>. Vancouver Sun<span class="printonly">. <a href="http://www.canada.com/vancouversun/news/story.html?id=83f35b4e-ac13-4c09-b8de-44d16750b70b&amp;k=58837" class="external free" title="http://www.canada.com/vancouversun/news/story.html?id=83f35b4e-ac13-4c09-b8de-44d16750b70b&amp;k=58837" rel="nofollow">http://www.canada.com/vancouversun/news/story.html?id=83f35b4e-ac13-4c09-b8de-44d16750b70b&amp;k=58837</a></span><span class="reference-accessdate">. Retrieved on 2007-06-02</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Warning+issued+over+drug&amp;rft.atitle=&amp;rft.aulast=Fayerman&amp;rft.aufirst=Pamela&amp;rft.au=Fayerman%2C+Pamela&amp;rft.date=February+27+2007&amp;rft.pub=Vancouver+Sun&amp;rft_id=http%3A%2F%2Fwww.canada.com%2Fvancouversun%2Fnews%2Fstory.html%3Fid%3D83f35b4e-ac13-4c09-b8de-44d16750b70b%26k%3D58837&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-44"><b><a href="#cite_ref-44" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFHanekamp_B.2C_Zijlstra_J.2C_Tulleken_J.2C_Ligtenberg_J.2C_van_der_Werf_T.2C_Hofstra_L2005">Hanekamp B, Zijlstra J, Tulleken J, Ligtenberg J, van der Werf T, Hofstra L (2005). "Serotonin syndrome and rhabdomyolysis in venlafaxine poisoning: a case report". <i>Neth J Med</i> <b>63</b> (8): 316–8. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16186642" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16186642">PMID 16186642</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Serotonin+syndrome+and+rhabdomyolysis+in+venlafaxine+poisoning%3A+a+case+report&amp;rft.jtitle=Neth+J+Med&amp;rft.aulast=Hanekamp+B%2C+Zijlstra+J%2C+Tulleken+J%2C+Ligtenberg+J%2C+van+der+Werf+T%2C+Hofstra+L&amp;rft.au=Hanekamp+B%2C+Zijlstra+J%2C+Tulleken+J%2C+Ligtenberg+J%2C+van+der+Werf+T%2C+Hofstra+L&amp;rft.date=2005&amp;rft.volume=63&amp;rft.issue=8&amp;rft.pages=316%E2%80%938&amp;rft_id=info:pmid/16186642&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-45"><b><a href="#cite_ref-45" title="">^</a></b> <cite style="font-style:normal" class="web" id="CITEREF.5BNo_Authors_listed.5D">[No Authors listed]. <a href="http://www.clinicaltrials.gov/ct/show/NCT00001483" class="external text" title="http://www.clinicaltrials.gov/ct/show/NCT00001483" rel="nofollow">"Acute Effectiveness of Additional Drugs to the Standard Treatment of Depression"</a>. ClinicalTrials.gov<span class="printonly">. <a href="http://www.clinicaltrials.gov/ct/show/NCT00001483" class="external free" title="http://www.clinicaltrials.gov/ct/show/NCT00001483" rel="nofollow">http://www.clinicaltrials.gov/ct/show/NCT00001483</a></span><span class="reference-accessdate">. Retrieved on 23 June 2005</span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=bookitem&amp;rft.btitle=Acute+Effectiveness+of+Additional+Drugs+to+the+Standard+Treatment+of+Depression&amp;rft.atitle=&amp;rft.aulast=%5BNo+Authors+listed%5D&amp;rft.au=%5BNo+Authors+listed%5D&amp;rft.pub=ClinicalTrials.gov&amp;rft_id=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct%2Fshow%2FNCT00001483&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-46"><b><a href="#cite_ref-46" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFGoeringer_K.2C_McIntyre_I.2C_Drummer_O2001">Goeringer K, McIntyre I, Drummer O (2001). "Postmortem tissue concentrations of venlafaxine". <i>Forensic Sci Int</i> <b>121</b> (1-2): 70–5. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1016%2FS0379-0738%2801%2900455-8" class="external text" title="http://dx.doi.org/10.1016%2FS0379-0738%2801%2900455-8" rel="nofollow">10.1016/S0379-0738(01)00455-8</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11516890" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11516890">PMID 11516890</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Postmortem+tissue+concentrations+of+venlafaxine&amp;rft.jtitle=Forensic+Sci+Int&amp;rft.aulast=Goeringer+K%2C+McIntyre+I%2C+Drummer+O&amp;rft.au=Goeringer+K%2C+McIntyre+I%2C+Drummer+O&amp;rft.date=2001&amp;rft.volume=121&amp;rft.issue=1-2&amp;rft.pages=70%E2%80%935&amp;rft_id=info:doi/10.1016%2FS0379-0738%2801%2900455-8&amp;rft_id=info:pmid/11516890&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-CNSDrugs2001-Wellington-47"><b><a href="#cite_ref-CNSDrugs2001-Wellington_47-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFWellington_K.2C_Perry_C2001">Wellington K, Perry C (2001). "Venlafaxine extended-release: a review of its use in the management of major depression". <i>CNS Drugs</i> <b>15</b> (8): 643–69. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.2165%2F00023210-200115080-00007" class="external text" title="http://dx.doi.org/10.2165%2F00023210-200115080-00007" rel="nofollow">10.2165/00023210-200115080-00007</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11524036" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11524036">PMID 11524036</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Venlafaxine+extended-release%3A+a+review+of+its+use+in+the+management+of+major+depression&amp;rft.jtitle=CNS+Drugs&amp;rft.aulast=Wellington+K%2C+Perry+C&amp;rft.au=Wellington+K%2C+Perry+C&amp;rft.date=2001&amp;rft.volume=15&amp;rft.issue=8&amp;rft.pages=643%E2%80%9369&amp;rft_id=info:doi/10.2165%2F00023210-200115080-00007&amp;rft_id=info:pmid/11524036&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-JCPT_JClinPharmTher2006-shams-48"><b><a href="#cite_ref-JCPT_JClinPharmTher2006-shams_48-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFShams_ME_et_al2006">Shams ME et al (2006). "CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine". <i>J Clin Pharm Ther</i> <b>31</b> (5): 493–502. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1111%2Fj.1365-2710.2006.00763.x" class="external text" title="http://dx.doi.org/10.1111%2Fj.1365-2710.2006.00763.x" rel="nofollow">10.1111/j.1365-2710.2006.00763.x</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16958828" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/16958828">PMID 16958828</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=CYP2D6+polymorphism+and+clinical+effect+of+the+antidepressant+venlafaxine&amp;rft.jtitle=J+Clin+Pharm+Ther&amp;rft.aulast=Shams+ME+et+al&amp;rft.au=Shams+ME+et+al&amp;rft.date=2006&amp;rft.volume=31&amp;rft.issue=5&amp;rft.pages=493%E2%80%93502&amp;rft_id=info:doi/10.1111%2Fj.1365-2710.2006.00763.x&amp;rft_id=info:pmid/16958828&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-49"><b><a href="#cite_ref-49" title="">^</a></b> <a href="http://www.snpedia.com/index.php/Rs2032583" class="external text" title="http://www.snpedia.com/index.php/Rs2032583" rel="nofollow">SNPedia</a></li>
<li id="cite_note-50"><b><a href="#cite_ref-50" title="">^</a></b> <cite style="font-style:normal" class="book" id="CITEREFKarch2006">Karch, Amy (2006). <i>2006 Lippincott's Nursing Drug Guide</i>. Philadephia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams &amp; Wilkins. <a href="/wiki/Special:BookSources/1582554366" class="internal">ISBN 1-58255-436-6</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=2006+Lippincott%27s+Nursing+Drug+Guide&amp;rft.aulast=Karch&amp;rft.aufirst=Amy&amp;rft.au=Karch%2C+Amy&amp;rft.date=2006&amp;rft.place=Philadephia%2C+Baltimore%2C+New+York%2C+London%2C+Buenos+Aires%2C+Hong+Kong%2C+Sydney%2C+Tokyo&amp;rft.pub=Lippincott+Williams+%26+Wilkins&amp;rft.isbn=1-58255-436-6&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid18072153-51"><b><a href="#cite_ref-pmid18072153_51-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFThundiyil_JG.2C_Kearney_TE.2C_Olson_KR2007">Thundiyil JG, Kearney TE, Olson KR (March 2007). "Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System". <i>J Med Toxicol</i> <b>3</b> (1): 15–9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18072153" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/18072153">PMID 18072153</a>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Evolving+epidemiology+of+drug-induced+seizures+reported+to+a+Poison+Control+Center+System&amp;rft.jtitle=J+Med+Toxicol&amp;rft.aulast=Thundiyil+JG%2C+Kearney+TE%2C+Olson+KR&amp;rft.au=Thundiyil+JG%2C+Kearney+TE%2C+Olson+KR&amp;rft.date=March+2007&amp;rft.volume=3&amp;rft.issue=1&amp;rft.pages=15%E2%80%939&amp;rft_id=info:pmid/18072153&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-52"><b><a href="#cite_ref-52" title="">^</a></b> <a href="http://www.erowid.org/experiences/exp.php?ID=37418" class="external text" title="http://www.erowid.org/experiences/exp.php?ID=37418" rel="nofollow">Do Not Combine!Venlafaxine (Effexor) &amp; Cannabis.</a></li>
<li id="cite_note-53"><b><a href="#cite_ref-53" title="">^</a></b> [<a href="http://www.erowid.org/experiences/exp.php?ID=66068" class="external free" title="http://www.erowid.org/experiences/exp.php?ID=66068" rel="nofollow">http://www.erowid.org/experiences/exp.php?ID=66068</a> Combo Sent Me Into Seizure. Venlafaxine (Effexor XR) &amp; Cannabis.]</li>
<li id="cite_note-pmid17267806-54"><b><a href="#cite_ref-pmid17267806_54-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSantos_PM.2C_L.C3.B3pez-Garc.C3.ADa_P.2C_Navarro_JS.2C_Fern.C3.A1ndez_AS.2C_S.C3.A1daba_B.2C_Vidal_JP2007">Santos PM, López-García P, Navarro JS, Fernández AS, Sádaba B, Vidal JP (February 2007). "<a href="http://ajp.psychiatryonline.org/cgi/content/full/164/2/349" class="external text" title="http://ajp.psychiatryonline.org/cgi/content/full/164/2/349" rel="nofollow">False positive phencyclidine results caused by venlafaxine</a>". <i>Am J Psychiatry</i> <b>164</b> (2): 349. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="neverexpand"><a href="http://dx.doi.org/10.1176%2Fappi.ajp.164.2.349" class="external text" title="http://dx.doi.org/10.1176%2Fappi.ajp.164.2.349" rel="nofollow">10.1176/appi.ajp.164.2.349</a></span>. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17267806" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/17267806">PMID 17267806</a><span class="printonly">. <a href="http://ajp.psychiatryonline.org/cgi/content/full/164/2/349" class="external free" title="http://ajp.psychiatryonline.org/cgi/content/full/164/2/349" rel="nofollow">http://ajp.psychiatryonline.org/cgi/content/full/164/2/349</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=False+positive+phencyclidine+results+caused+by+venlafaxine&amp;rft.jtitle=Am+J+Psychiatry&amp;rft.aulast=Santos+PM%2C+L%C3%B3pez-Garc%C3%ADa+P%2C+Navarro+JS%2C+Fern%C3%A1ndez+AS%2C+S%C3%A1daba+B%2C+Vidal+JP&amp;rft.au=Santos+PM%2C+L%C3%B3pez-Garc%C3%ADa+P%2C+Navarro+JS%2C+Fern%C3%A1ndez+AS%2C+S%C3%A1daba+B%2C+Vidal+JP&amp;rft.date=February+2007&amp;rft.volume=164&amp;rft.issue=2&amp;rft.pages=349&amp;rft_id=info:doi/10.1176%2Fappi.ajp.164.2.349&amp;rft_id=info:pmid/17267806&amp;rft_id=http%3A%2F%2Fajp.psychiatryonline.org%2Fcgi%2Fcontent%2Ffull%2F164%2F2%2F349&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
<li id="cite_note-pmid11901076-55"><b><a href="#cite_ref-pmid11901076_55-0" title="">^</a></b> <cite style="font-style:normal" class="" id="CITEREFSena_SF.2C_Kazimi_S.2C_Wu_AH2002">Sena SF, Kazimi S, Wu AH (2002). "<a href="http://clinchem.org/cgi/content/full/48/4/676" class="external text" title="http://clinchem.org/cgi/content/full/48/4/676" rel="nofollow">False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine</a>". <i>Clin. Chem.</i> <b>48</b> (4): 676–7. <a href="http://www.ncbi.nlm.nih.gov/pubmed/11901076" class="external" title="http://www.ncbi.nlm.nih.gov/pubmed/11901076">PMID 11901076</a><span class="printonly">. <a href="http://clinchem.org/cgi/content/full/48/4/676" class="external free" title="http://clinchem.org/cgi/content/full/48/4/676" rel="nofollow">http://clinchem.org/cgi/content/full/48/4/676</a></span>.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=False-positive+phencyclidine+immunoassay+results+caused+by+venlafaxine+and+O-desmethylvenlafaxine&amp;rft.jtitle=Clin.+Chem.&amp;rft.aulast=Sena+SF%2C+Kazimi+S%2C+Wu+AH&amp;rft.au=Sena+SF%2C+Kazimi+S%2C+Wu+AH&amp;rft.date=2002&amp;rft.volume=48&amp;rft.issue=4&amp;rft.pages=676%E2%80%937&amp;rft_id=info:pmid/11901076&amp;rft_id=http%3A%2F%2Fclinchem.org%2Fcgi%2Fcontent%2Ffull%2F48%2F4%2F676&amp;rfr_id=info:sid/en.wikipedia.org:Venlafaxine"><span style="display: none;">&#160;</span></span></li>
</ol>
</div>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=29" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<p><a name="Drug_information" id="Drug_information"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=30" title="Edit section: Drug information">edit</a>]</span> <span class="mw-headline">Drug information</span></h3>
<ul>
<li><a href="http://www.fda.gov/CDER/drug/infopage/effexor/default.htm" class="external text" title="http://www.fda.gov/CDER/drug/infopage/effexor/default.htm" rel="nofollow">U.S. Food and Drug Administration information on Effexor</a></li>
<li><a href="http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=2209" class="external text" title="http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=2209" rel="nofollow">Efexor patient information leaflet</a> Efexor patient information leaflet</li>
<li><a href="http://www.wyeth.com/content/ShowLabeling.asp?id=100" class="external text" title="http://www.wyeth.com/content/ShowLabeling.asp?id=100" rel="nofollow">Effexor XR prescribing information for healthcare professionals (pdf) (USA only)</a></li>
<li><a href="http://www.rxlist.com/cgi/generic/venlafax_pi.htm" class="external text" title="http://www.rxlist.com/cgi/generic/venlafax_pi.htm" rel="nofollow">Detailed Patient/Parent Information on Effexor</a></li>
<li><a href="http://www.merck.com/mmpe/lexicomp/venlafaxine.html#N18219E" class="external text" title="http://www.merck.com/mmpe/lexicomp/venlafaxine.html#N18219E" rel="nofollow">List of international brand names for Venlafaxine</a></li>
</ul>
<p><a name="Diagnostic_Tools" id="Diagnostic_Tools"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=31" title="Edit section: Diagnostic Tools">edit</a>]</span> <span class="mw-headline">Diagnostic Tools</span></h3>
<ul>
<li><a href="http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635" class="external text" title="http://www.qjmed.oxfordjournals.org/cgi/content/full/96/9/635" rel="nofollow">The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity</a></li>
</ul>
<p><a name="Patient_experiences" id="Patient_experiences"></a></p>
<h3><span class="editsection">[<a href="/w/index.php?title=Venlafaxine&amp;action=edit&amp;section=32" title="Edit section: Patient experiences">edit</a>]</span> <span class="mw-headline">Patient experiences</span></h3>
<ul>
<li><a href="http://www.nytimes.com/2007/05/06/magazine/06antidepressant-t.html?_r=1&amp;ei=5087%0A&amp;em=&amp;en=cdeb03773a3deee0&amp;ex=1178596800&amp;pagewanted=all&amp;oref=slogin" class="external text" title="http://www.nytimes.com/2007/05/06/magazine/06antidepressant-t.html?_r=1&amp;ei=5087%0A&amp;em=&amp;en=cdeb03773a3deee0&amp;ex=1178596800&amp;pagewanted=all&amp;oref=slogin" rel="nofollow">Stutz, Bruce "Self-Nonmedication" New York Times Magazine May 6, 2007</a></li>
</ul>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;;border:none;; font-size:xx-small;"><a href="/wiki/Template:Antidepressants" title="Template:Antidepressants"><span title="View this template" style=";;border:none;">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="/wiki/Template_talk:Antidepressants" title="Template talk:Antidepressants"><span title="Discussion about this template" style=";;border:none;">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:Antidepressants&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:Antidepressants&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="/wiki/Psychoanaleptic" title="Psychoanaleptic">Psychoanaleptics</a>: <a href="/wiki/Antidepressant" title="Antidepressant">antidepressants</a> (<a href="/wiki/ATC_code_N06#N06A_Antidepressants" title="ATC code N06">N06A</a>)</span></th>
</tr>
<tr style="height:2px;">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Monoamine_oxidase_inhibitor" title="Monoamine oxidase inhibitor">MAOIs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i>nonselective:</i> <i>non-reversible</i> (<a href="/wiki/Isocarboxazid" title="Isocarboxazid">Isocarboxazid</a>, <a href="/wiki/Iproclozide" title="Iproclozide">Iproclozide</a>, <a href="/wiki/Iproniazid" title="Iproniazid">Iproniazid</a>, <a href="/wiki/Nialamide" title="Nialamide">Nialamide</a>, <a href="/wiki/Phenelzine" title="Phenelzine">Phenelzine</a>, <a href="/wiki/Pheniprazine" title="Pheniprazine">Pheniprazine</a>) • <i>reversible</i> (<a href="/wiki/Tranylcypromine" title="Tranylcypromine">Tranylcypromine</a>)
<p><i><a href="/wiki/Monoamine_oxidase_A" title="Monoamine oxidase A">MAOA</a> (<a href="/wiki/Norepinephrine" title="Norepinephrine">N</a>/<a href="/wiki/Serotonin" title="Serotonin">S</a>):</i> <a href="/wiki/Clorgiline" title="Clorgiline">Clorgiline</a> • <a href="/wiki/Minaprine" title="Minaprine">Minaprine</a> • <i><a href="/wiki/Reversible_inhibitor_of_monoamine_oxidase_A" title="Reversible inhibitor of monoamine oxidase A">RIMAs</a></i> (<a href="/wiki/Befloxatone" title="Befloxatone">Befloxatone</a>, <a href="/wiki/Brofaromine" title="Brofaromine">Brofaromine</a>, <a href="/wiki/Cimoxatone" title="Cimoxatone">Cimoxatone</a>, <a href="/wiki/Harmaline" title="Harmaline">Harmaline</a>, <a href="/wiki/Moclobemide" title="Moclobemide">Moclobemide</a>, <a href="/wiki/Pirlindole" title="Pirlindole">Pirlindole</a>, <a href="/wiki/Toloxatone" title="Toloxatone">Toloxatone</a>)</p>
<i><a href="/wiki/Monoamine_oxidase_B" title="Monoamine oxidase B">MAOB</a> (<a href="/wiki/Dopamine" title="Dopamine">D</a>):</i> <a href="/wiki/Rasagiline" title="Rasagiline">Rasagiline</a> • <a href="/wiki/Selegiline" title="Selegiline">Selegiline</a> • <a href="/wiki/Pargyline" title="Pargyline">Pargyline</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Neurotransmitter_uptake_inhibitor" title="Neurotransmitter uptake inhibitor">RIs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"></div>
<table cellspacing="0" class="nowraplinks navbox-subgroup" style="width:100%;;;;">
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Serotonin_uptake_inhibitor" title="Serotonin uptake inhibitor">S RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Selective_serotonin_reuptake_inhibitor" title="Selective serotonin reuptake inhibitor">SS RI</a> (<a href="/wiki/Alaproclate" title="Alaproclate">Alaproclate</a>, <a href="/wiki/Citalopram" title="Citalopram">Citalopram</a>, <a href="/wiki/Dapoxetine" title="Dapoxetine">Dapoxetine</a>, <a href="/wiki/Escitalopram" title="Escitalopram">Escitalopram</a>, <a href="/wiki/Femoxetine" title="Femoxetine">Femoxetine</a>, <a href="/wiki/Fluoxetine" title="Fluoxetine">Fluoxetine</a>, <a href="/wiki/Fluvoxamine" title="Fluvoxamine">Fluvoxamine</a>, <a href="/wiki/Paroxetine" title="Paroxetine">Paroxetine</a>, <a href="/wiki/Sertraline" title="Sertraline">Sertraline</a>, <a href="/wiki/Vilazodone" title="Vilazodone">Vilazodone</a>, <a href="/wiki/Zimelidine" title="Zimelidine">Zimelidine</a>)<br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a>/<a href="/wiki/Tetracyclic_antidepressant" title="Tetracyclic antidepressant">Tetras</a></i> (<a href="/wiki/Cianopramine" title="Cianopramine">Cianopramine</a>, <a href="/wiki/Clomipramine" title="Clomipramine">Clomipramine</a>, <a href="/wiki/Nefazodone" title="Nefazodone">Nefazodone</a>, <a href="/wiki/Trazodone" title="Trazodone">Trazodone</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Norepinephrine_reuptake_inhibitor" title="Norepinephrine reuptake inhibitor">N RI</a> / <a href="/wiki/Adrenergic_uptake_inhibitor" title="Adrenergic uptake inhibitor">A RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Atomoxetine" title="Atomoxetine">Atomoxetine</a> • <a href="/wiki/Ciclazindol" title="Ciclazindol">Ciclazindol</a> • <a href="/wiki/Maprotiline" title="Maprotiline">Maprotiline</a> • <a href="/wiki/Nisoxetine" title="Nisoxetine">Nisoxetine</a> • <a href="/wiki/Oxaprotiline" title="Oxaprotiline">Oxaprotiline</a> • <a href="/wiki/Reboxetine" title="Reboxetine">Reboxetine</a> • <a href="/wiki/Talopram" title="Talopram">Talopram</a> • <a href="/wiki/Viloxazine" title="Viloxazine">Viloxazine</a><br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a>/<a href="/wiki/Tetracyclic_antidepressant" title="Tetracyclic antidepressant">Tetras</a></i> (<a href="/wiki/Amoxapine" title="Amoxapine">Amoxapine</a>, <a href="/wiki/Butriptyline" title="Butriptyline">Butriptyline</a>, <a href="/wiki/Desipramine" title="Desipramine">Desipramine</a>/<a href="/wiki/Lofepramine" title="Lofepramine">Lofepramine</a>, <a href="/wiki/Dibenzepin" title="Dibenzepin">Dibenzepin</a>, <a href="/wiki/Dosulepin_hydrochloride" title="Dosulepin hydrochloride">Dosulepin</a>, <a href="/wiki/Doxepin" title="Doxepin">Doxepin</a>, <a href="/wiki/Imipramine" title="Imipramine">Imipramine</a>, <a href="/wiki/Iprindole" title="Iprindole">Iprindole</a>, <a href="/wiki/Melitracen" title="Melitracen">Melitracen</a>, <a href="/wiki/Nitroxazepine" title="Nitroxazepine">Nitroxazepine</a>, <a href="/wiki/Nortriptyline" title="Nortriptyline">Nortriptyline</a>, <a href="/wiki/Protriptyline" title="Protriptyline">Protriptyline</a>, <a href="/wiki/Trimipramine" title="Trimipramine">Trimipramine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Dopamine_reuptake_inhibitor" title="Dopamine reuptake inhibitor">D RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Medifoxamine" title="Medifoxamine">Medifoxamine</a> • <a href="/wiki/Phenmetrazine" title="Phenmetrazine">Phenmetrazine</a> • <a href="/wiki/Vanoxerine" title="Vanoxerine">Vanoxerine</a><br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Amineptine" title="Amineptine">Amineptine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Serotonin-norepinephrine_reuptake_inhibitor" title="Serotonin-norepinephrine reuptake inhibitor">SN RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Bicifadine" title="Bicifadine">Bicifadine</a> • <a href="/wiki/Clovoxamine" title="Clovoxamine">Clovoxamine</a> • <a href="/wiki/Desvenlafaxine" title="Desvenlafaxine">Desvenlafaxine</a> • <a href="/wiki/Duloxetine" title="Duloxetine">Duloxetine</a> • <a href="/wiki/Indeloxazine" title="Indeloxazine">Indeloxazine</a> • <a href="/wiki/Milnacipran" title="Milnacipran">Milnacipran</a> • <a href="/wiki/Nefazodone" title="Nefazodone">Nefazodone</a> • <strong class="selflink">Venlafaxine</strong><br />
<i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Amitriptyline" title="Amitriptyline">Amitriptyline</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Norepinephrine-dopamine_reuptake_inhibitor" title="Norepinephrine-dopamine reuptake inhibitor">ND RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/Bupropion" title="Bupropion">Bupropion</a> • <a href="/wiki/Nomifensine" title="Nomifensine">Nomifensine</a></div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";padding-left:0em;padding-right:0em;background: LightYellow;">
<div style="padding:0em 0.75em;"><a href="/wiki/Serotonin-noradrenaline-dopamine_reuptake_inhibitor" title="Serotonin-noradrenaline-dopamine reuptake inhibitor">SND RI</a></div>
</td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><a href="/wiki/Brasofensine" title="Brasofensine">Brasofensine</a> • <a href="/wiki/Diclofensine" title="Diclofensine">Diclofensine</a> • <a href="/wiki/Tesofensine" title="Tesofensine">Tesofensine</a></div>
</td>
</tr>
</table>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Selective_serotonin_reuptake_enhancer" title="Selective serotonin reuptake enhancer">SSREs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Tianeptine" title="Tianeptine">Tianeptine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Adrenergic_antagonist" title="Adrenergic antagonist">AAs</a> at <a href="/wiki/Alpha-2_adrenergic_receptor" title="Alpha-2 adrenergic receptor">A2</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i><a href="/wiki/Tetracyclic_antidepressant" title="Tetracyclic antidepressant">Tetras</a></i> (<a href="/wiki/Mianserin" title="Mianserin">Mianserin</a>, <a href="/wiki/Mirtazapine" title="Mirtazapine">Mirtazapine</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Sigma_receptor#Agonists" title="Sigma receptor">SAs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><i><a href="/wiki/Tricyclic_antidepressant" title="Tricyclic antidepressant">TCAs</a></i> (<a href="/wiki/Opipramol" title="Opipramol">Opipramol</a>)</div>
</td>
</tr>
<tr style="height:2px">
<td></td>
</tr>
<tr>
<td class="navbox-group" style=";background: LightYellow;"><a href="/wiki/Melatonin_receptor" title="Melatonin receptor">MAs</a></td>
<td style="text-align:left;border-left:2px solid #fdfdfd;width:100%;padding:0px;;;" class="navbox-list navbox-even">
<div style="padding:0em 0.25em"><i><a href="/wiki/Melatonin_receptor#Agonists" title="Melatonin receptor">Melatonin receptor agonists</a></i> (<a href="/wiki/Agomelatine" title="Agomelatine">Agomelatine</a>)</div>
</td>
</tr>
</table>
</td>
</tr>
</table>
<table class="navbox" cellspacing="0" style=";">
<tr>
<td style="padding:2px;">
<table cellspacing="0" class="nowraplinks collapsible autocollapse" style="width:100%;background:transparent;color:inherit;;">
<tr>
<th style=";" colspan="2" class="navbox-title">
<div style="float:left; width:6em;text-align:left;">
<div class="noprint plainlinksneverexpand navbar" style="background:none; padding:0; font-weight:normal;;;border:none;; font-size:xx-small;"><a href="/wiki/Template:Phenethylamines" title="Template:Phenethylamines"><span title="View this template" style=";;border:none;">v</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="/wiki/Template_talk:Phenethylamines" title="Template talk:Phenethylamines"><span title="Discussion about this template" style=";;border:none;">d</span></a>&#160;<span style="font-size:80%;">•</span>&#160;<a href="http://en.wikipedia.org/w/index.php?title=Template:Phenethylamines&amp;action=edit" class="external text" title="http://en.wikipedia.org/w/index.php?title=Template:Phenethylamines&amp;action=edit" rel="nofollow"><span title="Edit this template" style=";;border:none;;">e</span></a></div>
</div>
<span style="font-size:110%;"><a href="/wiki/Phenethylamine" title="Phenethylamine">Phenethylamines</a></span></th>
</tr>
<tr style="height:2px;">
<td></td>
</tr>
<tr>
<td colspan="2" style="width:100%;padding:0px;;;" class="navbox-list navbox-odd">
<div style="padding:0em 0.25em"><a href="/wiki/2C-B" title="2C-B">2C-B</a> • <a href="/wiki/2C-C" title="2C-C">2C-C</a> • <a href="/wiki/2C-D" title="2C-D">2C-D</a> • <a href="/wiki/2C-E" title="2C-E">2C-E</a> • <a href="/wiki/2C-I" title="2C-I">2C-I</a> • <a href="/wiki/2C-N" title="2C-N">2C-N</a> • <a href="/wiki/2C-T-2" title="2C-T-2">2C-T-2</a> • <a href="/wiki/2C-T-21" title="2C-T-21">2C-T-21</a> • <a href="/wiki/2C-T-4" title="2C-T-4">2C-T-4</a> • <a href="/wiki/2C-T-7" title="2C-T-7">2C-T-7</a> • <a href="/wiki/2C-T-8" title="2C-T-8">2C-T-8</a> • <a href="/wiki/3C-E" title="3C-E">3C-E</a> • <a href="/wiki/4-Fluoroamphetamine" title="4-Fluoroamphetamine">4-FMP</a> • <a href="/wiki/Alfetamine" title="Alfetamine">Alfetamine</a> • <a href="/wiki/Amphetamine" title="Amphetamine">Amphetamine</a> • <a href="/wiki/Bupropion" title="Bupropion">Bupropion</a> • <a href="/wiki/Cathine" title="Cathine">Cathine</a> • <a href="/wiki/Cathinone" title="Cathinone">Cathinone</a> • <a href="/wiki/Clenbuterol" title="Clenbuterol">Clenbuterol</a> • <a href="/wiki/DESOXY" title="DESOXY">DESOXY</a> • <a href="/wiki/Dextroamphetamine" title="Dextroamphetamine">Dextroamphetamine</a> • <a href="/wiki/Methamphetamine" title="Methamphetamine">Methamphetamine</a> • <a href="/wiki/Diethylcathinone" title="Diethylcathinone">Diethylcathinone</a> • <a href="/wiki/Dimethylcathinone" title="Dimethylcathinone">Dimethylcathinone</a> • <a href="/wiki/4-chloro-2,5-dimethoxyamphetamine" title="4-chloro-2,5-dimethoxyamphetamine" class="mw-redirect">DOC</a> • <a href="/wiki/2,5-dimethoxy-4-bromoamphetamine" title="2,5-dimethoxy-4-bromoamphetamine" class="mw-redirect">DOB</a> • <a href="/wiki/2,5-dimethoxy-4-iodoamphetamine" title="2,5-dimethoxy-4-iodoamphetamine" class="mw-redirect">DOI</a> • <a href="/wiki/2,5-dimethoxy-4-methylamphetamine" title="2,5-dimethoxy-4-methylamphetamine" class="mw-redirect">DOM</a> • <a href="/wiki/Bk-MBDB" title="Bk-MBDB">bk-MBDB</a> • <a href="/wiki/Dopamine" title="Dopamine">Dopamine</a> • <a href="/wiki/Bromo-DragonFly" title="Bromo-DragonFly" class="mw-redirect">Br-DFLY</a> • <a href="/wiki/Ephedrine" title="Ephedrine">Ephedrine</a> • <a href="/wiki/Epinephrine" title="Epinephrine">Epinephrine</a> • <a href="/wiki/Escaline" title="Escaline">Escaline</a> • <a href="/wiki/Etafedrine" title="Etafedrine">Etafedrine</a> • <a href="/wiki/Fenfluramine" title="Fenfluramine">Fenfluramine</a> • <a href="/wiki/Levosalbutamol" title="Levosalbutamol">Levosalbutamol</a> • <a href="/wiki/Levomethamphetamine" title="Levomethamphetamine">Levomethamphetamine</a> • <a href="/wiki/MBDB" title="MBDB">MBDB</a> • <a href="/wiki/3,4-methylenedioxyamphetamine" title="3,4-methylenedioxyamphetamine" class="mw-redirect">MDA</a> • <a href="/wiki/MDMA" title="MDMA">MDMA</a> • <a href="/wiki/MDMC" title="MDMC" class="mw-redirect">MDMC</a> • <a href="/wiki/3,4-methylenedioxy-N-ethylamphetamine" title="3,4-methylenedioxy-N-ethylamphetamine" class="mw-redirect">MDEA</a> • <a href="/wiki/MDPV" title="MDPV">MDPV</a> • <a href="/wiki/Mescaline" title="Mescaline">Mescaline</a> • <a href="/wiki/Methcathinone" title="Methcathinone">Methcathinone</a> • <a href="/wiki/Norepinephrine" title="Norepinephrine">Norepinephrine</a> • <a href="/wiki/Phentermine" title="Phentermine">Phentermine</a> • <a href="/wiki/Salbutamol" title="Salbutamol">Salbutamol</a> • <a href="/wiki/Tyramine" title="Tyramine">Tyramine</a> • <strong class="selflink">Venlafaxine</strong></div>
</td>
</tr>
</table>
</td>
</tr>
</table>


<!-- 
NewPP limit report
Preprocessor node count: 27540/1000000
Post-expand include size: 257199/2048000 bytes
Template argument size: 97027/2048000 bytes
Expensive parser function count: 1/500
-->

<!-- Saved in parser cache with key enwiki:pcache:idhash:520574-0!1!0!default!!en!2 and timestamp 20090408064701 -->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org/wiki/Venlafaxine">http://en.wikipedia.org/wiki/Venlafaxine</a>"</div>
			<div id='catlinks' class='catlinks'><div id="mw-normal-catlinks"><a href="/wiki/Special:Categories" title="Special:Categories">Categories</a>:&#32;<span dir='ltr'><a href="/wiki/Category:Bicyclic_antidepressants" title="Category:Bicyclic antidepressants">Bicyclic antidepressants</a></span> | <span dir='ltr'><a href="/wiki/Category:Phenethylamines" title="Category:Phenethylamines">Phenethylamines</a></span> | <span dir='ltr'><a href="/wiki/Category:Serotonin-norepinephrine-dopamine_reuptake_inhibitors" title="Category:Serotonin-norepinephrine-dopamine reuptake inhibitors">Serotonin-norepinephrine-dopamine reuptake inhibitors</a></span></div><div id="mw-hidden-catlinks" class="mw-hidden-cats-hidden">Hidden categories:&#32;<span dir='ltr'><a href="/wiki/Category:Pages_with_DOIs_broken_since_2008" title="Category:Pages with DOIs broken since 2008">Pages with DOIs broken since 2008</a></span> | <span dir='ltr'><a href="/wiki/Category:All_articles_with_unsourced_statements" title="Category:All articles with unsourced statements">All articles with unsourced statements</a></span> | <span dir='ltr'><a href="/wiki/Category:Articles_with_unsourced_statements_since_March_2009" title="Category:Articles with unsourced statements since March 2009">Articles with unsourced statements since March 2009</a></span></div></div>			<!-- end content -->
						<div class="visualClear"></div>
		</div>
	</div>
		</div>
		<div id="column-one">
	<div id="p-cactions" class="portlet">
		<h5>Views</h5>
		<div class="pBody">
			<ul>
	
				 <li id="ca-nstab-main" class="selected"><a href="/wiki/Venlafaxine" title="View the content page [c]" accesskey="c">Article</a></li>
				 <li id="ca-talk"><a href="/wiki/Talk:Venlafaxine" title="Discussion about the content page [t]" accesskey="t">Discussion</a></li>
				 <li id="ca-edit"><a href="/w/index.php?title=Venlafaxine&amp;action=edit" title="You can edit this page. &#10;Please use the preview button before saving. [e]" accesskey="e">Edit this page</a></li>
				 <li id="ca-history"><a href="/w/index.php?title=Venlafaxine&amp;action=history" title="Past versions of this page [h]" accesskey="h">History</a></li>			</ul>
		</div>
	</div>
	<div class="portlet" id="p-personal">
		<h5>Personal tools</h5>
		<div class="pBody">
			<ul>
				<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Venlafaxine" title="You are encouraged to log in; however, it is not mandatory. [o]" accesskey="o">Log in / create account</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-logo">
		<a style="background-image: url(http://upload.wikimedia.org/wikipedia/en/b/bc/Wiki.png);" href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
	<div class='generated-sidebar portlet' id='p-navigation'>
		<h5>Navigation</h5>
		<div class='pBody'>
			<ul>
				<li id="n-mainpage-description"><a href="/wiki/Main_Page" title="Visit the main page [z]" accesskey="z">Main page</a></li>
				<li id="n-contents"><a href="/wiki/Portal:Contents" title="Guides to browsing Wikipedia">Contents</a></li>
				<li id="n-featuredcontent"><a href="/wiki/Portal:Featured_content" title="Featured content — the best of Wikipedia">Featured content</a></li>
				<li id="n-currentevents"><a href="/wiki/Portal:Current_events" title="Find background information on current events">Current events</a></li>
				<li id="n-randompage"><a href="/wiki/Special:Random" title="Load a random article [x]" accesskey="x">Random article</a></li>
			</ul>
		</div>
	</div>
	<div id="p-search" class="portlet">
		<h5><label for="searchInput">Search</label></h5>
		<div id="searchBody" class="pBody">
			<form action="/w/index.php" id="searchform"><div>
				<input type='hidden' name="title" value="Special:Search"/>
				<input id="searchInput" name="search" type="text" title="Search Wikipedia [f]" accesskey="f" value="" />
				<input type='submit' name="go" class="searchButton" id="searchGoButton"	value="Go" title="Go to a page with this exact name if one exists" />&nbsp;
				<input type='submit' name="fulltext" class="searchButton" id="mw-searchButton" value="Search" title="Search Wikipedia for this text" />
			</div></form>
		</div>
	</div>
	<div class='generated-sidebar portlet' id='p-interaction'>
		<h5>Interaction</h5>
		<div class='pBody'>
			<ul>
				<li id="n-aboutsite"><a href="/wiki/Wikipedia:About" title="Find out about Wikipedia">About Wikipedia</a></li>
				<li id="n-portal"><a href="/wiki/Wikipedia:Community_portal" title="About the project, what you can do, where to find things">Community portal</a></li>
				<li id="n-recentchanges"><a href="/wiki/Special:RecentChanges" title="The list of recent changes in the wiki [r]" accesskey="r">Recent changes</a></li>
				<li id="n-contact"><a href="/wiki/Wikipedia:Contact_us" title="How to contact Wikipedia">Contact Wikipedia</a></li>
				<li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Donate" title="Support us">Donate to Wikipedia</a></li>
				<li id="n-help"><a href="/wiki/Help:Contents" title="Guidance on how to use and edit Wikipedia">Help</a></li>
			</ul>
		</div>
	</div>
	<div class="portlet" id="p-tb">
		<h5>Toolbox</h5>
		<div class="pBody">
			<ul>
				<li id="t-whatlinkshere"><a href="/wiki/Special:WhatLinksHere/Venlafaxine" title="List of all English Wikipedia pages containing links to this page [j]" accesskey="j">What links here</a></li>
				<li id="t-recentchangeslinked"><a href="/wiki/Special:RecentChangesLinked/Venlafaxine" title="Recent changes in pages linked from this page [k]" accesskey="k">Related changes</a></li>
<li id="t-upload"><a href="/wiki/Wikipedia:Upload" title="Upload files [u]" accesskey="u">Upload file</a></li>
<li id="t-specialpages"><a href="/wiki/Special:SpecialPages" title="List of all special pages [q]" accesskey="q">Special pages</a></li>
				<li id="t-print"><a href="/w/index.php?title=Venlafaxine&amp;printable=yes" rel="alternate" title="Printable version of this page [p]" accesskey="p">Printable version</a></li>				<li id="t-permalink"><a href="/w/index.php?title=Venlafaxine&amp;oldid=282506397" title="Permanent link to this version of the page">Permanent link</a></li><li id="t-cite"><a href="/w/index.php?title=Special:Cite&amp;page=Venlafaxine&amp;id=282506397">Cite this page</a></li>			</ul>
		</div>
	</div>
	<div id="p-lang" class="portlet">
		<h5>Languages</h5>
		<div class="pBody">
			<ul>
				<li class="interwiki-de"><a href="http://de.wikipedia.org/wiki/Venlafaxin">Deutsch</a></li>
				<li class="interwiki-es"><a href="http://es.wikipedia.org/wiki/Venlafaxina">Español</a></li>
				<li class="interwiki-fr"><a href="http://fr.wikipedia.org/wiki/Venlafaxine">Français</a></li>
				<li class="interwiki-ko"><a href="http://ko.wikipedia.org/wiki/%EB%B2%A4%EB%9D%BC%ED%8C%8D%EC%8B%A0">한국어</a></li>
				<li class="interwiki-it"><a href="http://it.wikipedia.org/wiki/Venlafaxina">Italiano</a></li>
				<li class="interwiki-nl"><a href="http://nl.wikipedia.org/wiki/Venlafaxine">Nederlands</a></li>
				<li class="interwiki-pl"><a href="http://pl.wikipedia.org/wiki/Wenlafaksyna">Polski</a></li>
				<li class="interwiki-pt"><a href="http://pt.wikipedia.org/wiki/Venlafaxina">Português</a></li>
				<li class="interwiki-ru"><a href="http://ru.wikipedia.org/wiki/%D0%92%D0%B5%D0%BD%D0%BB%D0%B0%D1%84%D0%B0%D0%BA%D1%81%D0%B8%D0%BD">Русский</a></li>
				<li class="interwiki-fi"><a href="http://fi.wikipedia.org/wiki/Venlafaksiini">Suomi</a></li>
				<li class="interwiki-sv"><a href="http://sv.wikipedia.org/wiki/Venlafaxin">Svenska</a></li>
			</ul>
		</div>
	</div>
		</div><!-- end of the left (by default at least) column -->
			<div class="visualClear"></div>
			<div id="footer">
				<div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="/skins-1.5/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>
				<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="/images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>
			<ul id="f-list">
					<li id="lastmod"> This page was last modified on 8 April 2009, at 06:47 (UTC).</li>
					<li id="copyright">All text is available under the terms of the <a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Text_of_the_GNU_Free_Documentation_License" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="http://en.wikipedia.org/wiki/Wikipedia:Copyrights" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc.</a>, a U.S. registered <a class='internal' href="http://en.wikipedia.org/wiki/501%28c%29#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="http://en.wikipedia.org/wiki/Non-profit_organization" title="Non-profit organization">nonprofit</a> <a href="http://en.wikipedia.org/wiki/Charitable_organization" title="Charitable organization">charity</a>.<br /></li>
					<li id="privacy"><a href="http://wikimediafoundation.org/wiki/Privacy_policy" title="wikimedia:Privacy policy">Privacy policy</a></li>
					<li id="about"><a href="/wiki/Wikipedia:About" title="Wikipedia:About">About Wikipedia</a></li>
					<li id="disclaimer"><a href="/wiki/Wikipedia:General_disclaimer" title="Wikipedia:General disclaimer">Disclaimers</a></li>
			</ul>
		</div>
</div>

		<script type="text/javascript">if (window.runOnloadHook) runOnloadHook();</script>
<!-- Served by srv67 in 0.063 secs. --></body></html>
